

⑫

EUROPEAN PATENT APPLICATION

⑰ Application number: 85303450.2

⑤① Int. Cl.⁴: **C 07 C 83/10, A 61 K 31/165**

⑱ Date of filing: 15.06.85

⑲ Priority: 17.05.84 US 611251
04.04.85 US 719936

⑦① Applicant: E.R. Squibb & Sons, Inc.,
Lawrenceville-Princeton Road, Princeton,
N.J. 08540 (US)

④③ Date of publication of application: 21.11.85
Bulletin 35/47


⑦② Inventor: Karanewsky, Donald S., 8 Charred Oak Lane,
East Windsor New Jersey (US)
Inventor: Hesianger, Martin F.,
RD1, 291 Harborton-Rocktown Road, Lambertville New
Jersey (US)

④④ Designated Contracting States: AT BE CH DE FR GB IT
LI LU NL SE


⑦③ Representative: Thomas, Roger Tamlyn et al, D. Young &
Co, 10 Staple Inn, London WC1V 7RD (GB)

⑤② Arylhydroxamates

⑤⑦ Arylhydroxamates are provided having the structure



wherein R¹ is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkenyl, aralkyl, or




wherein n is 1 to 4 and X is hydroxy, alkoxy, amino, C₁-C₄-alkylamino or C₁-C₄-dialkylamino.

R² is hydrogen or lower alkyl; and

R³ is C₁-C₄-alkyl or C₁-C₄-alkenyl, aryl, arylalkyl, cycloalkyl, arylalkenyl, lower alkoxy, lower alkenyloxy, arylalkoxy or cycloalkyloxy. These compounds are useful as inhibitors of Δ⁵-lipoxygenase and as such are useful as anti-allergy agents.

ARYLHYDROXAMATES

The present invention relates to aryl-hydroxamates which are inhibitors of Δ^5 -lipoxygenase and as such are useful, for example, as antiallergy agents and for treating bronchial asthma. These compounds have the structural formula



wherein R^1 is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl or $(CH_2)_n\overset{\overset{O}{\parallel}}{C}-X$ wherein n is 1 to 4 and X is hydroxy, lower alkoxy, amino, C_1 - C_4 -alkylamino or C_1 - C_4 -dialkylamino;
 R^2 is hydrogen or lower alkyl; and
 R^3 is C_1 - C_{20} alkyl, C_3 - C_{20} alkenyl, aryl, aryl-alkyl, cycloalkyl, aryl-alkenyl, lower

alkoxy, lower alkenyloxy, aryloxy, aryl-alkoxy or cycloalkyloxy, but when R^3 is aryl, R^1 is other than H. The R^3 group may be in the o-, m- or p-position on the benzene ring.

5

Where R^1 is $-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-OH$ and R^2 is H, the above compounds may form binary or dibasic salts such as with alkali metal, such as a dilithium, disodium or dipotassium salt; where R^1 is other

10

than $-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-OH$ and R^2 is H, the above compounds will form only a monobasic salt. In addition, the compounds of formula I will form salts with dicyclohexylamine or other amines as well as with tris(hydroxymethyl)aminomethane and other amines as set out in U. S. Patent No. 4,294,759.

15

The term "lower alkyl" or "alkyl" as employed herein by itself or as part of another group includes both straight and branched chain radicals of up to 12 carbons, preferably 1 to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including a halo-substituent, such as F, Br, Cl or I or CF_3 , an alkoxy substituent, an aryl substituent, an alkyl-aryl substituent, a haloaryl substituent, a cycloalkyl substituent, an alkylcycloalkyl substituent, hydroxy, an alkylamino substituent, an alkanoylamino substituent, an arylcarbonylamino substituent, a nitro substituent, a cyano substituent, a thiol substituent or an alkylthio substituent.

30

35

The term " C_1 - C_{20} alkyl" as employed herein includes the above alkyl radicals of 1 to 8 carbons and more as well as alkyl radicals of up to and including 20 carbon atoms, preferably from 4 to 16 carbons, such as in addition to the C_4 to C_{12} alkyl radicals set out above, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosanyl including all isomers thereof with or without the above substituents.

10 The term "cycloalkyl" employed herein by itself or as part of another group includes saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 15 cycloheptyl, cyclooctyl, cyclodecyl and cyclo-dodecyl, any of which groups may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups, 1 or 2 lower alkoxy groups, an aryl group, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 20 alkanoylamino groups, 1 or 2 arylcarbonylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, 1 or 2 thiol groups and/or 1 or 2 alkylthio groups.

 The term "aryl" or "Ar" as employed herein 25 by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl, naphthyl, substituted phenyl or substituted naphthyl wherein the substituent on either the 30 phenyl or naphthyl may be 1 or 2 lower alkyl groups, 1 or 2 halogens (Cl, Br or F), 1 or 2 lower alkoxy groups, an aryl group, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 alkanoylamino groups, 1 or 2 aryl- 35 carbonylamino groups, 1 or 2 amino groups, 1

or 2 nitro groups, 1 or 2 cyano groups, 1 or 2 thiol groups and/or 1 or 2 alkylthio groups.

The term "aralkyl", "aryl-alkyl" or "aryl-lower alkyl" as used herein refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl.

The term "lower alkenyl" or "alkenyl" as employed herein by itself or as part of another group includes an unsaturated hydrocarbon group having from 3 to 8 carbons and a single carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl and the like.

The term " C_3 - C_{20} alkenyl" includes straight or branched chain radicals of from 3 to 20 carbons, preferably 4 to 16 carbons in the normal chain, which include one double bond in the normal chain, such as any of the lower alkenyl groups mentioned above as well as 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 2-tridecenyl, 3-tetradecenyl, 1-pentadecenyl, 2-hexadecenyl, 4-heptadecenyl, 7-octadecenyl, 6-nonadecenyl and 8-eicosenyl, including all isomers thereof and the like.

The term "aryl-alkenyl" as used herein refers to lower alkenyl groups as discussed above having an aryl substituent.

The term "lower alkoxy", "alkoxy", "lower alkenyloxy", "cycloalkoxy" or "aralkoxy" includes any of the above lower alkyl, alkyl, lower alkenyl, cycloalkyl or aralkyl groups linked to an oxygen atom.

The term "alkanoyl" as used herein by itself or as part of another group refers to a lower alkyl group linked to a carbonyl group.

The term "halogen" or "halo" as used herein refers to chlorine, bromine, fluorine or iodine with chlorine being preferred.

Preferred are those compounds of the invention wherein R^1 is alkyl, such as methyl, or


10 $-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-X$ wherein n is 2 to 4, X is OH, alkoxy or amino, R^2 is H and R^3 is C_4 to C_{16} alkyl, C_4 - C_{16} alkenyl, phenylalkyl, phenyl or phenylalkenyl and is in the para or meta position.

The various compounds of the invention may be prepared as described below.

Compounds of formula I wherein R^2 is H and R^3 is alkyl or aryl-alkyl may be prepared as follows.

The benzoic acid of the structure A

A



25


(wherein R^{3a} is C_3 - C_{20} alkenyl, alkenyloxy, aryloxy, cycloalkyloxy or aryl-alkenyl) is subjected to a coupling reaction by reacting A with an O-protected hydroxyl amine of the structure B

30

B $\text{NH}_2\text{-O}$ Protecting group

(wherein the protecting group is benzyl, tetrahydropyranyl, methylthiomethyl or methoxymethyl)

at a temperature of within the range of from about -15 to about 25°C, employing a molar ratio of B:A of within the range of from about 1:1 to about 2.5:1, in the presence of an activating catalyst such as 1-hydroxybenzotriazole and a coupling reagent such as N,N'-dicyclohexylcarbodiimide (DCC) and an organic base such as triethylamine to form hydroxamate II



The hydroxamate II is then reacted with halide C

C Hal-R^{1a}


(wherein Hal is I, Br or Cl and R^{1a} is the same as R^1 where R^1 is to be lower alkyl,

aryl, cycloalkyl, aralkyl or $(\text{CH}_2)_n\text{C(=O)-X}$ wherein X is lower alkoxy in the final product)

at a temperature of within the range of from about 50 to about 110°C, employing a molar ratio of C:II

of within the range of from about 1:1 to about 3:1, in the presence of a base such as sodium hydride and an inert organic solvent such as toluene or benzene to form compound III


5



The protected compound III is then subjected to hydrogenolysis and hydrogenation by treating compound III with hydrogen in the presence of a palladium hydroxide on carbon catalyst to form the compounds of the invention IV

15

IV



25

wherein R^1 is $(\text{CH}_2)_n\text{-CO}_2\text{alkyl}$, alkyl, aryl, cycloalkyl or aralkyl, R^2 is H and R^3 is $\text{C}_1\text{-C}_{20}$ alkyl, aryl-alkyl, cycloalkyloxy, lower alkoxy or


30

aryloxy. However, where R^1 is to be $(\text{CH}_2)_n\text{-C(=O)-OH}$, the ester group in IV may be removed by treating with an alkali metal hydroxide such as lithium hydride in an organic solvent such as dioxane or methanol.


35

Where R^1 in the final product is to be


$-\text{CH}_2-\overset{\text{O}}{\parallel}{\text{C}}-\text{X}$, that is, n is 1, and X is OH or alkoxy,
then the protected compound II will be reacted
5 with allyl bromide ($\text{BrCH}_2\text{CH}=\text{CH}_2$) to form the
intermediate IIIa
IIIa



which is then treated with ozone, Jones reagent
15 ($\text{H}_2\text{CrO}_4/\text{H}_2\text{SO}_4/\text{H}_2\text{O}$) and diazomethane to form the
ester IIIb
IIIb




Ester IIIb may then be subjected to hydrogenolysis
25 as described above to form the ester IVa of the
invention
IVa



which may then be hydrolyzed to the corresponding acid IVb.

5

IVb



10

Where it is desired to form compounds wherein R³ is C₃-C₂₀ alkenyl, or aryl-alkenyl and/or R¹ is lower alkenyl, the protecting group, where the protecting group is either tetrahydropyanyl or methoxymethyl, may be removed by treating
15 III or IIIb with acetic acid without reducing the double bond in the R³ group and/or in the R¹ group. Alternatively, when the protecting group is methylthiomethyl, it can be removed by treatment with CuO-CuCl₂ in aqueous acetone without reducing
20 the double bond in the R³ group or in the R¹ group.

Where it is desired to prepare compounds of

25


the invention wherein R¹ is $-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}-X$ and X is amino, alkylamino or dialkylamino (wherein each
25 alkyl of the dialkyl group is the same or different), then compound III wherein R¹

30

is $-(CH_2)_n-\overset{\overset{O}{\parallel}}{C}Oalkyl$ is hydrolyzed to the corresponding acid IIIA by reacting III with
30 lithium hydroxide in the presence of a solvent such as dioxane as described above

IIIA


5



The acid IIIA is then treated with an activating agent such as isobutylchloroformate, organic base such as triethylamine and inert organic solvent such as acetonitrile and reacted with ammonium hydroxide where X is amino or with an appropriate alkylamine or dialkylamine where X is alkylamino or dialkylamino, respectively, to form amide IIIB


IIIB

20



Compound IIIB where the protecting group is benzyl may then be subjected to hydrogenolysis and hydrogenation as described above to form IVA


IVA



(R^3 is alkyl and X is amino or alkylamino).

Compound IIIB where the protecting group is tetrahydropyranyl may also be treated with acetic acid to remove the protecting group to form the corresponding compound wherein R^3 is alkenyl.

5 Compounds of the invention wherein R^1 is hydrogen may be prepared by removing the protecting group of compound II, for example, by treating II, where the protecting group is tetrahydropyranyl, with an acid catalyst such as
10 pyridinium p-toluene sulfonate in the presence of an alcoholic solvent such as methanol, to form IIA
IIA



(wherein R^2 is hydrogen and R^3 is C_3 - C_{20}
20 alkenyl)

Compound IIA may be reduced as described above to form the corresponding compound wherein R^3 is C_3 to C_{20} alkyl.


25 Preparation of compounds of formula IIA wherein R^2 is alkyl, that is compound V, is described hereinafter.

30 Compounds of the invention wherein R^2 is alkyl and R^3 is C_1 - C_{20} alkyl or aryl-alkyl may be prepared by subjecting benzoic acid A to a coupling reacting as described above except that the hydroxylamine coupling reagent employed has the structur

D $\text{NH}_2\text{-O-alkyl}$

to form the hydroxamate V


5



10

The hydroxamate V is then reacted with halide C as described above to form the compound of the invention of the structure VI

15




20

(wherein R^{3a} is $\text{C}_3\text{-C}_{20}$ alkenyl, or aryl-alkenyl)

Compound VI may be reduced as described above to form the corresponding compound wherein R^3 is $\text{C}_3\text{-C}_{20}$ alkyl and/or may be hydrolyzed (where R^1 is


$-(\text{CH}_2)_n-\overset{\text{O}}{\parallel}{\text{C}}\text{Oalkyl}$) to form the corresponding acid

Compounds of formula I wherein R^3 is as defined above and preferably is aryl or cycloalkyl and R^2 is H may be prepared by treating the benzoic acid E



10 (wherein R^{3b} is preferably aryl or cycloalkyl but may be any of the R^3 groups described above)


with oxalyl chloride in the presence of an inert organic solvent such as benzene, ethyl ether or tetrahydrofuran under an inert atmosphere such as argon to form the corresponding acid chloride F



which is then reacted with a hydroxylamine G




in the presence of an inert organic solvent such as tetrahydrofuran and in an organic base such as triethylamine to form the compounds of the invention VII




(wherein R^{3b} is preferably aryl or cycloalkyl or any of the other R^3 groups defined above)

10 Compounds of formula I wherein R^2 is alkyl may be prepared from compound VII by treating VII with a base such as sodium hydride and an alkyl halide (Hal-Alkyl) in the presence of an inert organic solvent such as tetrahydrofuran and
15 dimethylformamide, to form compounds of the invention VIII



(wherein R^{3b} is preferably aryl or cycloalkyl or any of the other R^3 groups defined above)

25 In an alternative method, compounds of formula I of the invention may be prepared by subjecting benzoic acid A to a coupling reaction by reacting acid A with an amine salt of the
30 structure IX



5

20




25



The ester XI is then subjected to a deprotecting procedure wherein XI is treated with cupric oxide and cupric chloride in an aqueous organic solvent mixture such as aqueous acetone (in the case where the protecting group is CH_3SCH_2-) or XI is treated with H_2 in the presence of a palladium hydroxide on carbon catalyst in the case where the protecting group is $\text{C}_6\text{H}_5-\text{CH}_2-$; the deprotected compound is then immediately hydrolyzed by treatment with lithium hydroxide or other base in the presence of an inert organic solvent such as dioxane, methanol or acetonitrile to form the acid compound of the invention of the structure XII

15

XII




20

The amine salt IX may be prepared from the hydroxylamine of the structure H

HProtecting group $-\text{ONH}_2$

25

by reacting H with acid halide J


J

30


in the presence of 2,6-lutidine and methylene chloride to form the compound J

K Protecting group-ONHC(=O)(CH₂)_nHal

Compound K is then cyclized by reacting same with a
 5 base such as sodium hydride, in the presence of
 benzene to form the protected N-hydroxy lactam L



For the preparation of the lactam where the
 protecting group is CH₃SCH₂, the lactam L, where
 15 the protecting group is benzyl, can be deprotected
 by a hydrogenolysis reaction wherein L is treated
 with hydrogen in the presence of a palladium
 hydroxide on carbon catalyst and an inert organic
 solvent such as ethanol, methanol or ethyl acetate
 20 to form the hydroxy lactam XIII



Lactam XIII can be treated with a protecting
 compound M


30 M Hal-CH₂SCH₃

in the presence of weak base such as potassium
 carbonate or triethylamine and an inert organic

solvent such as dimethyl formamide to form the protected compound XIV

XIV

5




10 Either L or XIV is next hydrolyzed by treatment with base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in the presence of dioxane to form the starting amine salt IX.

15 The starting benzoic acid compound A wherein R³ is C₃-C₂₀ alkenyl, aryl-alkyl or arylalkenyl may be prepared by reacting the formylmethylbenzoate of structure N


N

20




25 with the phosphonium salt O

O



30 wherein R⁴ is alkyl or aryl-alkyl containing one less carbon atom in the alkyl chain than in the alkenyl of R^{3a}, in the presence of n-butyllithium and hexamethylphosphorus triamide (HMPA) and an

inert organic solvent such as tetrahydrofuran to form the ester A'



10 wherein is R³ C₃-C₂₀ alkenyl or aryl-alkenyl.
Hydrolysis with aqueous base gives benzoic
acids A.

15 Compounds of formulae I and A' wherein R³ is
C₁-C₂₀ alkyl or aryl-alkyl may be prepared from
corresponding compounds where R³ is C₃-C₂₀ alkenyl
or aryl-alkenyl by conventional hydrogenation
techniques such as by treatment with H₂ in the
presence of a palladium on carbon catalyst and an
alcohol solvent.

20 The starting benzoic acids wherein R³ is
aryl or cycloalkyl are commercially available
compounds.

25 The compounds of the invention are delta-5-
lipoxygenase inhibitors and prevent leukotriene
C₄ formation in macrophages (Samuelsson, B.,
Science, Vol. 220, p. 568-575, 1983). The
administration of compounds of this invention to
humans or animals provides a method for treating
allergy of a reagin or non-reagin nature. Asthma
30 is preferably treated but any allergy wherein
leukotrienes are thought to be involved as
pharmacological mediators of anaphylaxis can be
treated. For example, the compounds of this

invention can be used for treatment of such conditions as allergic rhinitis, food allergy and urticaria as well as asthma, bronchial asthma and asthmoid bronchitis.

5 An effective but essentially non-toxic quantity of the compound is employed in treatment.

10 The compounds of the invention can be administered orally, parenterally or by aerosol to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs, and the like in an effective amount within the dosage range of about 1 to 100 mg/kg, preferably about 1 to 50 mg/kg and especially about 2 to 25 mg/kg on a
15 regimen in single or 2 to 4 divided daily doses.

 The active substance can be utilized in a composition such as tablet, capsule, solution, suspension or aerosol containing about 5 to about 500 mg per unit of dosage of a compound or mixture
20 of compounds of formula I. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc. as called for by accepted pharmaceutical practice. Also as
25 indicated in the discussion above, certain members additionally serve as intermediates for other members of the group.

The following Examples represent preferred embodiments of the invention. Unless otherwise indicated, all temperatures are expressed in °C. TLC plates were visualized by spraying and heating with 5% phosphomolybdic acid in ethanol. HP-20 refers to a high porous divinylbenzene-polystyrene polymer resin.

Example 1

4-Decyl-N-hydroxy-N-methylbenzamide

10 A. Nonyltriphenylphosphonium Bromide
(Ref. Ono Pharmaceutical Patent #J57106-651,
p. 373)

 A magnetically stirred suspension of
1-bromononane (Aldrich, 40 g, 0.1931 M) and
15 triphenylphosphine (101.3 g, 0.3862 mole) was
heated at 100°C (oil bath) for 2 hours. The
resulting homogeneous solution was then cooled and
trituated with ether (8X) to remove most of the
unreacted triphenylphosphine. A viscous gum was
20 obtained which was dissolved in CH₂Cl₂ and
concentrated in vacuo to give the title
phosphonium salt as a light yellow, extremely
hygroscopic foam weighing 85 g (80.1%). TLC, neat
CH₂Cl₂, R_f = 0.78, PMA.

25

 B. (Z)-Methyl 4-(1-Decenyl)benzoate
(Ref. Same as for preparation of title A)

 To a mixture of the title A phosphonium salt
(18.22 g, 0.0332 M) dissolved in anhydrous THF
30 (200 ml) was added n-BuLi (17.6 ml of a 2.1 M
solution, 0.037 M) at -78°C under argon with
stirring. After stirring for 30 minutes,
dry hexamethylphosphorus triamide (HMPA) (29.0 ml)

was added to the orange mixtur . After stirring for an additional 10 minutes, p-formylmethylbenzoate (4.816 g, 0.029 mole) in dry THF (32 ml) was added dropwise over a 1.5 hours period at
5 -78°C. Then it was warmed to 0°C (ice bath) over a 30-minute period. H₂O was added (80 ml) and the mixture extracted with ethyl acetate. The organic layer was washed with saturated NH₄Cl, brine, and then dried over anhydrous MgSO₄. Concentration
10 in vacuo gave 18.2 g of a yellow solid which was flash chromatographed on Whatman LPS-1 silica gel eluting with (9:1) Hex:CH₂Cl₂. Product containing fractions were concentrated in vacuo to yield the title Wittig product as a pale yellow oil weighing
15 3.77 g (47%). TLC 9:1, Hex-EtOAc, R_f=0.43, PMA. ¹H NMR (60 MHz, CDCl₃): δ 0.87 (3H, t, -(CH₂)₇CH₃)

C. (Z)-4-(1-Decenyl)benzoic acid

(Ref. Same as for preparation of title A)

20 To a stirred solution of the title B methyl ester (3.7 g, 0.0135 M) in CH₃OH (60 ml) and THF (10 ml) was added a 2.0 N NaOH solution (21 ml) and the mixture was heated at 70°C under argon for 2.0 hours. Concentration in vacuo left a
25 white solid which was dissolved in EtOAc and washed with 5% KHSO₄ and brine, and dried over anhydrous Na₂SO₄. Concentration in vacuo left a white solid which was slurried in petroleum ether and filtered to give the title free acid as white
30 crystals with m.p. = 71°-73°C. 3.03 g (84.4%) obtained. TLC (2:1) Hex-EtOAc, R_f=0.24, PMA. ¹H NMR (60 MHz, CDCl₃); δ 0.87 (3H, t, -(CH₂)₇CH₃),

Microanalysis Calc'd for $C_{17}H_{24}O_2$: C, 78.42,

H, 9.29

Found: C, 78.29; H, 9.32

5 D. (Z)-4-(1-Decenyl)-N-benzyloxybenzamide

To a stirred solution of the title C acid (3.03 g, 11.64 mM) in dry CH_2Cl_2 (35 ml) was added 1-hydroxybenzotriazole (1.89 g, 13.97 mM, 1.2 eq.) and N,N'-dicyclohexylcarbodiimide (2.88 g, 13.97
10 mM, 1.2 eq.). After one hour at room temperature under argon, O-benzylhydroxylamine hydrochloride (4.64 g, 29.1 mM, 2.5 eq.) and Et_3N (4.06 ml, 29.1 mM, 2.5 eq.) were added and the mixture stirred for an additional two hours. The crude mixture
15 was filtered (2X), evaporated, taken up in ethyl acetate, filtered again and then washed successively with 5% $KHSO_4$, saturated $NaHCO_3$, and brine. Concentration in vacuo left a white solid which was flash chromatographed on LPS-1 silica
20 gel eluting with (9:1) Hex-EtOAc. Product containing fractions were concentrated in vacuo to a white solid which was recrystallized once from ethyl acetate-hexane to give 3.79 g (89.1%) of the desired title O-benzylhydroxamate as a white
25 crystalline solid with m.p. =70°-71° and consistent NMR (270 MHz, $CDCl_3$) spectral data. TLC (1:1) EtOAc-Hex, R_f product=0.71, UV + PMA. Microanalysis Calc'd for $C_{24}H_{31}NO_2$: C, 78.86;
H, 8.55; N, 3.83.
Found: C, 79.11; H, 8.66; N, 3.88

E. (2)4-(1-Decenyl)-N-benzyloxy-N-methylbenzamide

To a solution of the title D benzylhydroxamate (600 mg, 1.64 mM) in dry toluene (5 ml) was added 5
prewashed NaH (45 mg, 1.80 mM) and the mixture stirred for 20 minutes at room temperature under argon. Excess methyl iodide (0.313 ml, 4.92 mM, 3 eq) was added and the mixture was refluxed for 5 hours, then cooled and partitioned between 10
5% KHSO₄ and ethyl acetate. The organic phase was washed with brine, dried over anhydrous Na₂SO₄ and evaporated to a yellow oil which was chromatographed on Whatman LPS-1 silica gel eluting with (3:2) pet ether-ether. Product containing 15
fractions was evaporated to give 600 mg (96%) of the title N-methylated product as a light yellow oil with consistent NMR (60 MHz, CDCl₃) spectral data. TLC (1:1) Pet ether-ether, R_f prod.=0.45, UV + PMA.

20

F. 4-Decyl-N-hydroxy-N-methylbenzamide

Argon was bubbled through a solution of the title E N-methylhydroxamate (600 mg) in CH₃OH (10 ml) for 5 minutes before adding 20% palladium 25
hydroxide on carbon (100 mg, 15% by weight) and stirring under H₂ for 2 hours. Mixture was then filtered through Celite, evaporated, taken up in EtOAc, filtered through a small plug of Whatman LPS-1 silica gel and evaporated to an off-white 30
crystalline solid. One recrystallization from EtOAc-Hex gave 386 mg (84%) of the desired title N-methyl hydroxamic acid as off-white crystals with consistent NMR (CDCl₃, 270 MHz) spectral data. TLC

(1:1) EtOAc-Hex, $R_f=0.56$, UV + PMA. m.p. =
61°-63°C.

Microanalysis calcd for $C_{18}H_{29}NO_2$: C, 74.18;
H, 10.03; N, 4.81
Found: C, 74.07; H, 10.02; N, 4.81

Example 2

(Z)-4-[[4-(1-Decenyl)benzoyl]hydroxyamino]-
butanoic acid

A. O-Tetrahydropyran-2-ylhydroxylamine

With gentle heating N-hydroxyphthalimide
(10.0 g, 61.4 mM) was dissolved in dry CH_2Cl_2 (70
ml) and dioxane (80 ml), then dihydropyran (6.16
ml, 67.6 mM, 1.1 eq) and p-toluenesulfonic acid
monohydrate (200 mg, 2% by weight) were added and
the mixture stirred for 2 hours at room
temperature under argon. The mixture was then
washed successively with saturated $NaHCO_3$ (2X) and
brine, dried over anhydrous Na_2SO_4 and evaporated
to a white solid. The solid was triturated with
hexane and filtered to give 13.43 g (89%) of
O-tetrahydropyranyl hydroxyphthalimide as a white
solid m.p. 123-125°C with consistent NMR (60 MHz,
 $CDCl_3$) spectral data. TLC (1:1) EtOAc-Hex,
 $R_f=0.75$, UV + PMA.

To a stirred solution of the O-THP hydroxy-
phthalimide (13.0 g, 52.6 mM) in dry benzene (30
ml) was added methyl hydrazine (2.82 ml, 53.0 mM)
and the mixture heated at 80°C for 15 minutes under
argon. The mixture was filtered and concentrated
to a 50 ml volume then vacuum distilled to give
5.46 g (89%) of the desired THP-hydroxylamine as a

clear colorless oil with b.p.=70°C (10 mm Hg).

Note: Compound crystallizes upon cooling in freezer under argon. TLC (1:1) EtOAc-Hex, R_f 0.31, UV + PMA.

5

B. (Z)-4-(1-Decenyl)-N-(tetrahydropyran-2-yloxy)benzamide

To a solution of the Example 1 title C acid (1.0 g, 3.84 mM) in dry CH_2Cl_2 (15 ml) was added
10 1-hydroxybenzotriazole (623 mg, 4.61 mM, 1.2 eq) and DCC (951 mg, 4.61, 1.2 eq) and the mixture stirred for one hour under argon at room temperature. O-THP-hydroxylamine (900 mg, 7.68 mM, 2 eq) was added and the mixture stirred for 3
15 hours at room temperature. The mixture was filtered, evaporated, taken up in ethyl acetate, filtered again, evaporated and chromatographed on Whatman LPS-1 silica gel eluting with (8:2) Hex-EtOAc. Product containing fractions were
20 evaporated to give 890 mg (65%) of the title coupled product as a clear, colorless oil with consistent NMR (CDCl_3 , 270 MHz) spectral data. TLC (1:1) EtOAc-Hex, R_f 0.67, UV + PMA.

25

C. (Z)-4-[[4-(1-Decenyl)benzoyl]tetrahydropyran-2-yloxyamino]butanoic acid, ethyl ester

Prewashed NaH (70 mg, 2.9 mM, 1.2 eq) was added to a solution of the title B THP-hydroxamate
30 (870 mg, 2.42 mM) in dry toluene (10 ml) and the mixture stirred at room temperature under argon for 15 minutes. Ethyl-4-iodobutyrate (1.76 g, 7.26 mM, 3 eq) was added and the mixture was

refluxed overnight. The mixture was partitioned between 5% KHSO_4 and EtOAc, the organic phase washed with brine, dried over anhydrous Na_2SO_4 and evaporated to an oil. The crude oil was run
5 through neutral alumina (act=1) to remove any remaining starting material eluting with (8:2) Hex-Acetone. Product fractions were evaporated and then chromatographed on Whatman LPS-1 silica gel eluting with (95:5) Hex-Acetone. Product
10 fractions were evaporated to give 1.059 g (92%) of the desired title N-alkylated product as a clear oil with consistent NMR (CDCl_3 , 270 MHz) spectral data. TLC (8:2) Hex-Acetone, R_f =0.43, UV + PMA.

15 D. (Z)-4-[[4-(1-Decenyl)benzoyl]hydroxy-
amino]butanoic acid, ethyl ester

A stirred mixture of the title C O-THP hydroxamate (1.041 g, 2.20 mM) in (3:2:2) HOAc:THF: H_2O (6 ml) was heated at 55°C overnight
20 under argon. The mixture was then carefully partitioned between saturated NaHCO_3 and EtOAc, the organic layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated to give 897 mg (crude) of the desired title hydroxamic acid as a
25 yellow oil. TLC (1:1) EtOAc-Hex, R_f 0.56, UV + PMA, product streaks to baseline.

E. (Z)-4-[[4-(1-Decenyl)benzoyl]hydroxy-
amino]butanoic acid

30 To a solution of the title D crude ethyl ester (879 mg) in dioxane (10 ml) was added a 1.0 N LiOH solution (4.4 ml, 2 eq) and the mixture stirred for 1.5 hours at room temperature under

argon. The mixture was then partitioned between 5% KHSO_4 and EtOAc, the organic phase washed with brine, dried over anhydrous Na_2SO_4 and evaporated to a solid. One recrystallization from EtOAc-Hex gave 638 mg (80% combined analytical yield for last 2 steps) of the desired hydroxamic acid as straw colored crystals with consistent NMR (CDCl_3 , 270 MHz) spectral data and with m.p.=81°-83°C. TLC, EtOAc, R_f =0.34, UV + PMA.

Microanalysis Calcd for $\text{C}_{21}\text{H}_{31}\text{NO}_4$: C, 69.77;
H, 8.64; N, 3.88
Found: C, 69.64; H, 8.70; N, 3.70

Example 3

(Z)-4-[[4-(1-Decenyl)benzoyl]hydroxyamino]-butanoic acid

A. 4-Chloro-N-benzyloxy-butyramide

A solution of O-benzylhydroxyamine hydrochloride (22.69 g, 0.1418 M) and 2,6-lutidine (33 ml, 0.2836 M) in anhydrous CH_2Cl_2 (200 ml) was cooled to 0°C and chlorobutyryl chloride (15.9 ml, 0.1418 M) was then added dropwise under argon. The yellow mixture was stirred for 1 hour at room temperature before adding it to a 5% KHSO_4 solution. The organic layer was washed with saturated NaHCO_3 , brine and then concentrated in vacuo to a white solid which was finely ground in a mortar and pestle, rinsed with hexane and filtered to yield 32 g (99%) of title chloramide as a white powder, m.p. 58-61°C. NMR (CDCl_3 , 60 MHz) was consistent for the desired product. TLC (1:1) EtOAc-Hex, R_f = 0.36, PMA + UV.

B. N-Benzyloxy-piperid-2-one

To a magnetically stirred suspension of NaH (prewashed with hexanes, 1.9 g, 79.1 mM) in anhydrous benzene (100 ml) was added the title A chloramide, (15 g, 65.9 mM) dropwise in dry benzene (25 ml) at room temperature. The mixture was heated at 75°C (oil bath). After 3 hours, another 100 mg (4.12 mM) of prewashed NaH was added and heating continued for another 3 hours. The mixture was then added carefully to cold 5% KHSO₄ and ethyl acetate and the organic layer washed with brine, dried over anhydrous Na₂SO₄ and concentrated in vacuo to a white solid (12.6 g). This was triturated with hexane, then recrystallized from ethyl acetate-hexane to give 6.05 g (48%) of title hydroxamate as white granular crystals m.p. 80-81°C with consistent NMR spectral data. Further product could be isolated from the mother liquor by flash chromatography.

C. N-Hydroxy-piperid-2-one

In a dry Parr bottle was added title B hydroxamate (4.0 g, 20.9 mM) dissolved in absolute ethanol (60 ml). Argon was bubbled through the solution for 5 minutes and Pd(OH)₂, 20% on carbon (480 mg, 12% by weight) was then added. The reaction mixture was shaken on a Parr apparatus for 3 hours, then filtered through a plug of silica gel covered with dry Celite. The filtrate was concentrated in vacuo to give 2.05 g (97%) of the desired title hydroxamic acid, as an off-white crystalline solid m.p. 82-83°C with consistent H¹-NMR spectral data. TLC (9:1) CH₂Cl₂-CH₃OH, R_f = 0.30, UV and PMA single spot.

D. N-Methylthiomethoxy-piperid-2-one

To a stirred mixture of the title C hydroxamic acid (2.0 g, 19.8 mM) and chloromethyl methylsulfide (1.97 ml, 23.5 mM) in DMF (25 ml) under argon was added powdered K_2CO_3 (4.14 g, 30 mM) and the mixture stirred for 3 hours at room temperature. The yellow mixture was partitioned between 5% $KHSO_4$ and ethyl acetate, the organic layer washed with brine, dried over anhydrous Na_2SO_4 , and concentrated in vacuo to a light yellow crystalline solid. The solid was slurried in petroleum ether and filtered to give 1.59 g (50%) of the desired title thioether as a white crystalline solid m.p. 64-66°C with consistent H^1 -NMR (60 MHz, $CDCl_3$) spectral data. TLC (7:3, Hex-Acetone, R_f = 0.32, PMA) single spot.

E. 4-(N-Methylthiomethoxyamino)butanoic acid, lithium salt

To a stirred mixture of the title D methylthiomethyl ether (1.45 g, 8.99 mM) in dioxane (10 ml) was added a 1.0 N lithium hydroxide solution (18 ml, 18 mM, 2 eq.) and the mixture stirred overnight under argon. The mixture was then acidified to pH 8.0 using a few drops of glacial acetic acid and the title crude lithium salt was used directly in the next coupling step. TLC (9:1, CH_2Cl_2 - CH_3OH , R_f =0.35, PMA) single, more polar spot.

F. (Z)-4-[[4-(1-Decenyl)benzoyl]methyl-
thiomethoxyamino]butanoic acid

To a stirred mixture of the Example 1 Part
C acid (2.16 g, 8.3 mM) in acetone (28 ml) and
5 Et₃N (1.27 ml, 9.13 mM) at -10°C and under argon
was added isobutylchloroformate (1.24 ml, 9.13 mM,
1.1 eq.) and the mixture stirred for 30 minutes at
-10°C (dry ice/acetone). The resulting mixed
anhydride solution was then filtered into a
10 dioxane solution of the title E lithium salt at
-15°C, stirred for 10 minutes at -15°C, then at
room temperature overnight. The reaction mixture
was partitioned between 5% KHSO₄ and EtOAc, the
organic layer washed with brine, dried over
15 anhydrous Na₂SO₄ and concentrated in vacuo to a
light yellow oil. Crude reaction mixture of the
title F amide was used directly for subsequent
preparation of the methyl ester. TLC (9:1,
CH₂Cl₂-CH₃OH, R_f = 0.19, UV and PMA).

20

G. (Z)-4-[[4-(1-Decenyl)benzoyl]methyl-
thiomethoxyamino]butanoic acid,
methyl ester

An ethereal solution of diazomethane was
25 added by pipette portions to a stirred, cooled
(0°C, ice-H₂O) mixture of the crude title F acid
in ether (50 ml). After 1 hour at 0°C, the
mixture was rotovaped to an oil (3.55 g) which was
flash chromatographed on Whatman LPS-1 silica gel
30 eluting with EtOAc-hexane (2:8) to give title
methyl ester (655 mg, 18% for overall conversion of
acid to ester) as a clear oil with consistent

^1H -NMR (CDCl_3 , 60 MHz) spectral data. TLC (1:1, EtOAc-Hex, $R_f = 0.65$, UV and PMA) single spot.

5 H. (Z)-4-[[4-(1-Decenyl)benzoyl]hydroxy-
amino]butanoic acid

Ref. Narasaka, K, et al. Bull. Chem. Soc. Japan
45, p. 3724 (1972)

1) To a stirred solution of title G ester
10 (523 mg, 1.24 mM) in 1% aqueous acetone (5 ml) was
added CuO (198 mg, 2.47 mM, 2 eq.) and $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ (211 mg, 1.24 mM, 1 eq.). The mixture was
stirred at room temperature for 45 minutes and then
refluxed for 2.5 hours. Crude black mixture was
15 diluted with EtOAc, filtered through Celite, washed
with saturated NH_4Cl (3X), and filtered through
anhydrous MgSO_4 . Concentration in vacuo of the
filtrate left a dark green oil which was taken up
in EtOAc, washed with 1.0 M H_2SO_4 , dried over
20 anhydrous Na_2SO_4 and concentrated in vacuo to a
brown oil (464 mg). TLC (1:1, EtOAc-Hex, product
streaks, UV and PMA) indicated 1 more polar
impurity. Crude compound was used directly for
subsequent hydrolysis of methyl ester.

25 2) To a stirred solution of the crude
methyl ester (464 mg, 1.24 mM) in dioxane (4 ml)
was added a 1.0N LiOH solution (2.5 ml, 2.5 mM)
and the mixture stirred at room temperature under
30 argon for 45 minutes. The mixture was then
partitioned between 5% KHSO_4 and EtOAc, the
organic layer washed with brine, dried over
anhydrous Na_2SO_4 and concentrated in vacuo to an

orange oil. One recrystallization from ethyl acetate-hexane gave 305 mg of the crude title hydroxamic acid containing a more polar, baseline impurity. An HP-20 column was run to remove this
5 impurity.

The crude acid (302 mg) was dissolved in 2 ml of 1.0N LiOH to prepare the di-lithium salt. This solution was chromatographed on an HP-20 column (200 ml bed volume, 1 inch diameter
10 column) eluting with a gradient of H₂O (100%) to CH₃CN (100%). Product containing fractions were concentrated in vacuo to a tan oil (175 mg). The oil was dissolved in 5 ml H₂O, acidified with 5% KHSO₄, extracted with EtOAc and the organic layer
15 washed with brine, then dried over anhydrous Na₂SO₄ and concentrated in vacuo to a light tan crystalline solid. One recrystallization from EtOAc-Hex yielded 157 mg (35%) of the title hydroxamic acid as tan crystals (m.p. = 70°-72°C)
20 with consistent NMR (270 MHz, CDCl₃) spectral data. TLC (7:2:1, *i*-PrOH-NH₄OH•H₂O, R_f=0.54, UV and PMA) single spot.

Microanalysis Calcd for C₂₁H₃₁NO₄: C, 69.78;
25 H, 8.64; N, 3.87
Found: C, 69.60; H, 8.58; N, 3.91

Example 4

4-[(3-Decylbenzoyl)hydroxyamino]butanoic acid

30 A. 3-Formyl methylbenzoate

To a stirred solution of 3-carboxybenzaldehyde (Pfaltz & Bauer, supplier, 1.0 g, 6.66 mM) in dry THF (30 ml) at 0°C was added by

pipetted portion, an ethereal solution of diazomethane. After TLC indicated the reaction was complete, the reaction mixture was evaporated in vacuo to give 1.0 g (92%) of the desired title methyl ester as a yellow, low melting, crystalline solid with consistent NMR (CDCl_3 , 60 MHz) spectral data. TLC (1:1) EtOAc-hex, $R_f = 0.84$, UV and PMA.

B. (Z)-Methyl 3-(1-Decenyl)benzoate

To a stirred solution of the phosphonium salt $\text{CH}_3(\text{CH}_2)_8\text{P}^+\text{Ph}_3\text{Br}^-$, (prepared as described in Example 1 Part A) (4.72 g, 8.6 mM, 1.4 eq.) in anhydrous THF (42 ml) under argon and maintained at -78°C (dry ice/acetone) was added dropwise a 2.5M solution of n-butyllithium in hexanes (2.44 ml, 6.09 mM, 1 eq.). Fifteen minutes after completed addition, HMPA (6.34 ml, 36.5 mM, 6 eq.) was added to the orange-red solution followed by dropwise addition of the title A aldehyde (1.0 g, 6.09 mM) in THF (10 ml) over a 1.0 hour period. The mixture was warmed to 0°C (ice bath) over a 30 minute period and then added to 100 ml of H_2O . The solution was extracted with ethyl acetate, washed with saturated NH_4Cl and evaporated in vacuo to an oil. The crude oil was flash chromatographed on Whatman LPS-1 silica gel eluting with (8:2) hexane- CH_2Cl_2 . Product containing fractions were evaporated to give 1.436 g (86%) of the desired title Wittig product as a colorless oil with consistent NMR (CDCl_3 , 60 MHz) spectral data. TLC (1:1) EtOAc-Hex, $R_f = 0.90$, UV and PMA.

C. (Z)-3-(1-Decenyl)benzoic acid

To a stirred mixture of the title B methyl ester (1.409 g, 5.13 mM) in dioxane (20 ml) under argon was added 1.0 N LiOH (7.7 ml, 7.7 mM, 1.5 eq.) and the mixture heated at 50°C (oil bath) for 75 minutes. The mixture was cooled, partitioned between 5% KHSO₄ and EtOAc, the organic phase washed with brine and dried over anhydrous Na₂SO₄. Evaporation in vacuo gave 1.36 g (99%) of the desired title acid as a low melting, white crystalline solid with consistent NMR (60 MHz, CDCl₃) spectral data. TLC (1:1) EtOAc-hex, R_f acid = 0.51, UV and PMA.

15 D(1). 4-(N-Benzzyloxyamino)butanoic acid, lithium salt

To a stirred solution of the title protected hydroxamic acid (1.5 g, 7.8 mM) from Example 3, Part B in p-dioxane (20 ml) and under argon was added 1.0 N LiOH (15.7 ml, 15.7 mM). The yellow solution was then refluxed for 4 hours, cooled and then acidified to pH 8.0 with a few drops of glacial acetic acid. The crude title product mixture was then used in the next step. TLC (9:1, CH₂Cl₂-CH₃OH, R_f = 0.31, PMA + UV) indicated one more polar product spot.

D(2). (Z)-4-[[3-(1-Decenyl)benzoyl]benzyl-oxyamino]butanoic acid, methyl ester

30 To a solution of the title C acid (1.35 g, 5.18 mM) in acetone (20 ml) and Et₃N (590 µl, 5.7 mM, 1.1 eq.) at -10°C (dry ice/acetone) was added ethyl chloroformate (545 µl, 5.7 mM, 1.1 eq.) and

the mixture stirred under argon at -10°C for 1 hour. The mixture was filtered into a stirred, cooled (-10°C) solution of the title D(1) lithium salt ($\text{PhCH}_2\text{ONH}(\text{CH}_2)_3\text{CO}_2^-\text{Li}^+$) in dioxane (7.11 mM, 1.4 eq.) and then stirred at room temperature under argon for 2 hours. The mixture was partitioned between 5% KHSO_4 and EtOAc, the organic layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated in vacuo to an oil. TLC (9:1) CH_2Cl_2 - CH_3OH , R_f acid = 0.41, UV and PMA.

The resulting crude acid was dissolved in ether (50 ml), cooled to 0°C and treated with an ethereal solution of diazomethane. The crude mixture was evaporated to an oil and then chromatographed on alumina (act.=2) eluting with (9:1) hexane-acetone. Product containing fractions were concentrated in vacuo to give 1.348 g (56%) of the desired title methyl ester as a light yellow oil. TLC (1:1) EtOAc-hex, R_f CH_3 ester = 0.52, UV and PMA.

E. 4-[(3-Decylbenzoyl)hydroxyamino]-
butanoic acid, methyl ester

Argon was bubbled through a solution of the title D benzylhydroxamate (1.348 g, 2.9 mM) in absolute ethanol (30 ml) for 5 minutes before adding 20% palladium hydroxide on carbon (162 mg) and stirring under H_2 overnight. The mixture was filtered through a layered plug of Celite over Whatman LPS-1 silica gel and then evaporated to a brown oil. A flash chromatography on LPS-1 silica gel eluting with (9:1) benzene-EtOAc gave 350 mg

(32%) of the desired title hydroxamic acid as a clear il. TLC (1:1) EtOAc-hex, $R_f = 0.61$, UV and PMA.

5 F. 4-[(3-Decylbenzoyl)hydroxyamino]-
butanoic acid

To a stirred solution of the title E methyl ester (350 mg, 0.927 mM) in dioxane (5 ml) was added 1.0 N LiOH (1.9 ml, 1.9 mM, 2 eq.) and the
10 mixture stirred at room temperature for 2 hours. The clear yellow solution was partitioned between 5% KHSO_4 and EtOAc, the organic phase washed with brine, dried over Na_2SO_4 and evaporated to an
15 off-white crystalline solid. One recrystallization from ethyl acetate-hexane gave 191 mg (57%) of the desired title acid as straw colored crystals with m.p. $77^\circ\text{--}79^\circ\text{C}$ and consistent NMR spectral data (270 MHz, CDCl_3).

20 Microanalysis Calcd for $\text{C}_{21}\text{H}_{33}\text{NO}_4$: C, 69.39;
H, 9.15; N, 3.85
Found: C, 69.18; H, 9.14; N, 3.82

Example 5

25 4-[(2-Decylbenzoyl)hydroxyamino]butanoic acid,
dilithium salt

A. 2-Formyl methylbenzoate

To a stirred solution of 2-carboxybenzaldehyde (5.0 g, 33.3 mM) in ether (100 ml) and
30 THF (5 ml) at 0°C was added an ethereal solution of diazomethane by pipette portions until methyl ester formation was complete (i.e., a light yellow color persists). The mixture was evaporated to

giving 5.48 g (98%) of the desired title aldehyde as a light yellow oil with consistent NMR (CDCl_3 , 60 MHz) spectral data. TLC (1:1) EtOAc-Hex, R_f product=0.83, UV and PMA, single spot.

5

B. Methyl 2-(1-Decenyl)benzoate

To a stirred, cooled (-78°C , dry ice/acetone) solution of nonyltriphenylphosphonium bromide (prepared as described in Example 1 Part A) (12.09 g, 22 mM, 1.2 eq.) in dry THF (125 ml) was added dropwise under argon a 2.5M solution of n-BuLi in hexane (7.32 ml, 18.3 mM, 1 eq.). Twenty minutes after completed addition HMPA (19 ml, 110 mM, 6 eq.) was added followed by dropwise addition of the title A aldehyde (3.0 g, 183 mM) in 25 ml of THF over a 1.5 hour period. The mixture was warmed to 0°C (ice bath) over a 30 minute period, then added to 200 ml of H_2O and extracted (2X) with ethyl acetate. The organic phase was washed with saturated NH_4Cl , dried over anhydrous Na_2SO_4 and evaporated to a thick brown oil. Crude oil was flash chromatographed on LPS-1 silica gel eluting with (8:2) Hex- CH_2Cl_2 . Product containing fractions were evaporated to give 1.65 g (33%) of the desired title Wittig product (mixture of cis and trans isomers obtained) as a clear oil with consistent NMR (CDCl_3 , 60MHz) spectral data. TLC (1:1) EtOAc-Hex, R_f product=0.80, UV and PMA, single spot.

30

C. 2-(1-Decenyl)benzoic acid

To a stirred solution of the title B methyl ester (1.61 g, 5.87 mM) in dioxane (30 ml) was

added a 1.0N LiOH solution (11.7 ml, 11.7 mM, 2 eq.) and the mixture heated at 75°C (oil bath) under argon for 2 hours. The mixture was cooled, partitioned between 5% KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to give 1.5 g (98%) of the desired title acid as a light yellow oil with consistent NMR (CDCl₃, 60MHz) spectral data. TLC (1:1) EtOAc-Hex, R_f product=0.51, streaks, UV and PMS, single spot.

D. 4-(Benzyloxyamino)butanoic acid,
tetrabutylammonium salt

To a stirred solution of the compound prepared in Example 3 Part B (5.74 g, 30.0 mM) in dioxane (50 ml) was added tetrabutylammonium hydroxide (36 mM, 23.4 ml of a 40% solution) under argon and the mixture stirred at room temperature overnight. Excess base was neutralized with 1.0N HCl (6 ml, 6 mM) and then the crude mixture was evaporated. Residue was azeotroped (4X) with CH₃CN to insure dryness, then stored under vacuum. TLC (9:1) CH₂Cl₂-CH₃OH, R_f product=0.48, UV and PMA, single spot.

E. 4-[[2-(1-Decenyl)benzoyl]benzyloxy-
amino]butanoic acid, methyl ester

To a cooled (0°C, ice bath) solution of the title C acid (1.65 g, 6.34 mM) in dry CH₂Cl₂ (10 ml) and Et₃N (0.976 ml, 7.0 mM, 1.1 eq.) was added diethylchlorophosphate (1.01 ml, 7.0 mM, 1.1 eq.). The mixture was stirred for 1 hour at room temperature under argon and then 5 g of the title

D salt in 5 ml of methylene chloride was added. The resulting mixture was stirred at room temperature for 2 hours. The mixture was then partitioned between 5% KHSO_4 and EtOAc, the organic phase washed with brine, dried over anhydrous Na_2SO_4 and evaporated to give a crude oil. TLC (1:1) EtOAc-Hex, $R_f=0.23$, UV and PMA.

To prepare the title methyl ester, the crude oil was dissolved in ether (45 ml) and THF (5 ml), cooled to 0°C (ice bath) and treated with an ethereal solution of diazomethane. The reaction mixture was evaporated to an oil (3.33 g) which was taken up in CH_2Cl_2 and flash chromatographed on Whatman LPS-1 silica gel eluting with a (9:1) Hex-Acetone. Product containing fractions were evaporated to give 419 mg (14.2%) of the desired title hydroxamate methyl ester as a light yellow oil with consistent NMR (CDCl_3 , 60 MHz) spectral data. TLC (9:1) EtOAc-Hex, $R_f=0.72$, both isomers are visible, UV and PMA.

F. 4-[(2-Decylbenzoyl)hydroxyamino]-
butanoic acid, methyl ester

Argon was bubbled through a solution of the title E benzylhydroxamate (393 mg, 0.844 mM) in absolute EtOH (15 ml) for 5 minutes before adding 20% palladium hydroxide on carbon (59 mg) and shaking the mixture under H_2 on a Parr apparatus for 7 hours. The mixture was filtered through a layered plug of Celite and Whatman LPS-1 silica gel and evaporated to give 300 mg (94%) of the desired title hydroxamic acid as a tan oil with consistent

NMR (60 MHz, CDCl_3) spectral data. TLC (1:1) EtOAc-Hex, $R_f = 0.52$, UV and PMA.

5 G. 4-[(2-Decylbenzoyl)hydroxyamino]-
 butanoic acid, dilithium salt

To a stirred solution of the title F methyl ester (300 mg, 0.795 mM) in dioxane (4 ml) was added a 1.0N LiOH solution (1.6 ml, 1.6 mM, 2 eq.) and the mixture stirred under argon for 3 hours.
10 The mixture was diluted with H_2O , extracted with ether (to remove a non-polar impurity), the aqueous layer acidified to pH 2 with 1.0N HCl and then re-extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous
15 Na_2SO_4 and evaporated to a brown oil. TLC (9:1) CH_2Cl_2 - CH_3OH , R_f acid=0.11, UV and PMA.

The crude oil was dissolved in 1.0N LiOH (3 ml) and chromatographed on HP-20 eluting with a gradient of neat H_2O + (50:50) H_2O - CH_3CN . Product
20 containing fractions were combined and lyophilized to give 120 mg (40%) of the desired title acid as a white powder with consistent NMR spectral data.

Microanalysis Calcd for $\text{C}_{21}\text{H}_{31}\text{NO}_4\text{Li}_2$: C, 67.19;
25 H, 8.32; N, 3.73
 Found: C, 67.58; H, 8.77; N, 3.72

Example 6

30 4-[(4-Decylbenzoyl)hydroxyamino]butanoic acid,
 ethyl ester

A. (Z)-4-[[4-(1-Decenyl)benzoyl]benzyl-
 oxyamino]butanoic acid, ethyl ester

Prewashed sodium hydride (188 mg, 7.52 mM,

1.1 eq.) was added to a solution of hydroxamate prepared in Example 1 Part D (2.5 g, 6.84 mM) in dry toluene (14 ml) and the mixture stirred at room temperature under argon for 15 minutes. Ethyl-
5 4-iodobutyrate (3.31 g, 13.68 mM, 2.0 eq.) was then added and the mixture refluxed overnight. The crude mixture was cooled, partitioned between 5% KHSO_4 and EtOAc, the organic layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated
10 to an oil. The oil was dissolved in CH_2Cl_2 and flash chromatographed on Whatman LPS-1 silica gel eluting with (3:2) pet ether-ether. Product containing fractions were evaporated to give 2.82 g (86%) of the desired title alkylated product as a
15 light yellow oil with consistent NMR (270 MHz, CDCl_3) spectral data. TLC (9:1) CH_2Cl_2 -EtOAc, R_f product=0.52, UV + PMA.

20 B. 4-[(4-Decylbenzoyl)hydroxyamino]-
butanoic acid, ethyl ester

Argon was bubbled through a solution of the title B hydroxamate (481 mg, 1.003 mM) in absolute ethanol (10 ml) for 5 minutes before adding 20% palladium hydroxide on carbon (58 mg), and stirring
25 under H_2 for 4 hours. The mixture was then filtered through a layered plug of Celite over LPS-1 silica gel, evaporated to a white solid and recrystallized from EtOAc-Hex to give 340 mg (87%) of the desired title hydroxamic acid as a white
30 crystalline solid with m.p.=68°-69°C and consistent NMR (270MHz, CDCl_3) spectral data. TLC (1:1) EtOAc-Hex, R_f 0.43, UV + PMA.

Microanalysis Calcd for $C_{23}H_{37}NO_4$: C, 70.55;

H, 9.52; N, 3.58

Found: C, 70.64; H, 9.59; N, 3.45

5

Example 7

(Z)-4-[[4-(1-Decenyl)benzoyl]methoxyamino]butanoic
acid, dicyclohexylamine salt(1:1)

A. (Z)-4-(1-Decenyl)-N-methoxybenzamide

To a solution of the benzoic acid prepared
10 in Example 1 Part C (2.0 g, 7.68 mM) in dry
 CH_2Cl_2 (20 ml) was added 1-hydroxybenzotriazole
(1.25 g, 9.22 mM, 1.2 eq.) and N,N'-dicyclohexyl-
carbodiimide (1.90 g, 9.22 mM, 1.2 eq.) and the
mixture stirred for 1 hour at room temperature.
15 Methoxylamine hydrochloride (1.28 g, 15.36 mM, 2
eq.) and triethylamine (2.14 ml, 15.36 mM, 2 eq.)
were added, the mixture stirred for 3 hours at
room temperature, then filtered, evaporated, taken
up in ethyl acetate and filtered again. The
20 organic phase was washed successively with 5%
 $KHSO_4$, saturated $NaHCO_3$ and brine, then dried over
anhydrous Na_2SO_4 and evaporated to an oil. The
crude oil was flash chromatographed on LPS-1
silica gel eluting with (7:3) hexane-ethyl
25 acetate. Product containing fractions were
evaporated to give 2.023 g (91%) of the desired
title product, 1.664 g of cis isomer, 359 mg of
trans isomer as a low melting white solid with
consistent NMR ($CDCl_3$, 60MHz) spectral data. TLC
30 (1:1) EtOAc-Hex, R_f =0.39 UV and PMA.

B. (Z)-4-[[4-(1-Decenyl)benzoyl]methoxy-
amino]butanoic acid, ethyl ester

To a solution of the title A methyl
hydroxamate (400 mg, 1.38 mM) in dry toluene (6
5 ml) was added prewashed NaH (38 mg, 1.52 mM) and
the mixture stirred for 20 minutes at room
temperature. Ethyl-4-iodobutyrate (668 mg, 2.76
mM) was added and the mixture was refluxed
overnight under argon. The mixture was cooled,
10 partitioned between 5% KHSO₄ and ethyl acetate and
the organic phase washed with brine, dried over
anhydrous Na₂SO₄ and evaporated to an oil. The
crude oil was flash chromatographed on LPS-1
silica gel eluting with (3:2) petroleum
15 ether-Et₂O. Product containing fractions were
evaporated to give 539 mg (96.6%) of the desired
title N-alkylated product as a light yellow oil
with consistent NMR (CDCl₃, 270MHz) spectral data.
TLC (9:1) CH₂Cl₂-EtOAc, R_f prod. = 0.57, UV and
20 PMA, single spot.

C. (Z)-4-[[4-(1-Decenyl)benzoyl]methoxy-
amino]butanoic acid

To a solution of the title B ethyl ester
25 (435 mg, 1.08 mM) in dioxane (10 ml) was added
1.0N LiOH (2.20 ml, 2 eq.) and the mixture stirred
at room temperature under argon for two hours.
The mixture was then partitioned between 5% KHSO₄
and ethyl acetate, the organic phase washed with
30 brine, dried over anhydrous Na₂SO₄ and evaporated
to an oil. Crude oil was flash chromatographed on
LPS-1 silica gel eluting successively with (85-15)
Hex-Acetone and (95-5) CH₂Cl₂-CH₃OH. Product

containing fractions were evaporated to give 234 mg (58%) of the title acid as a clear oil with consistent NMR (270MHz, CDCl_3) spectral data.

5 D. (Z)-4-[[4-(1-Decenyl)benzoyl]methoxy-
 amino]butanoic acid, dicyclohexylamine
 salt(1:1)

 The dicyclohexylamine salt was prepared by
dissolving the title C acid in EtOAc (1 ml) and
10 treating it with dicyclohexylamine (126 μl , 1.1
eq.). The mixture was evaporated and then
crystallized from cold petroleum ether to give 309
mg (89% conversion from acid) of the title methyl
hydroxamate as the dicyclohexylamine salt.

15

Microanalysis Calcd for $\text{C}_{34}\text{H}_{56}\text{N}_2\text{O}_4$: C, 73.34;
 H, 10.14; N, 5.03
Found: C, 73.60; H, 10.26; N, 4.94

20

Example 8

N-(4-Amino-4-oxobutyl)-4-decyl-N-hydroxybenzamide

A. (Z)-4-[[4-(1-Decenyl)benzoyl]benzyl-
 oxyamino]butanoic acid

 To a solution of the ethyl ester prepared as
25 described in Example 6 Part A (547 mg, 1.14 mM) in
dioxane (5 ml) was added 1.0N LiOH (2.3 ml, 2 eq.)
and the mixture stirred for 3 hours under argon at
room temperature. The mixture was then partitioned
between 5% KHSO_4 and EtOAc, the organic layer
30 washed with brine, dried over anhydrous Na_2SO_4 and
evaporated to give 489 mg (95%) of the title acid
as a clear oil with consistent NMR (60 MHz, CDCl_3)

spectral data. TLC (1:1) EtOAc-Hex, R_f acid=0.09, UV and PMA.

5 B. N-(4-Amino-4-oxobutyl)-4-(1-decenyl)-N-benzyloxy benzamide

To a solution of the title A acid (489 mg, 1.08 mM) and Et_3N (181 μl , 1.3 mM) in dry CH_3CN (5 ml) was added isobutylchloroformate (169 μl , 1.3 mM, 1.2 eq.) and the mixture stirred for 1 hour at room temperature under argon. Concentrated NH_4OH (3 ml) was added dropwise, the mixture was stirred for 30 minutes, then it was partitioned between 1.0N HCl and EtOAc. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 and
15 evaporated to an oil. The crude oil was chromatographed on alumina (neutral activity = 2) with (1:1) EtOAc-Hex and (9:1) CH_2Cl_2 - CH_3OH followed by a chromatography on Whatman LPS-1 silica gel eluting with neat EtOAc. Product
20 containing fractions were evaporated to give 290 mg (59%) of the title amide as a clear oil with consistent NMR (CDCl_3 , 270 MHz) spectral data. TLC: EtOAc neat, R_f = 0.14, UV and PMA.

25 C. N-(4-Amino-4-oxobutyl)-4-decyl-N-hydroxybenzamide

Argon was bubbled through a solution of the title B benzylhydroxamate (290 mg) in CH_3OH (5 ml) for 5 minutes before adding 20% palladium hydroxide
30 on carbon (35 mg, 12% by weight) and stirring under H_2 for 2 hours. The mixture was filtered through Celite, evaporated, taken up in EtOAc, filtered through anhydrous MgSO_4 powder and evaporated to an

off-white solid. Two recrystallizations (from EtOAc-Hex, then acetone-Hex) gave 139 mg (60%) of the title amide as straw colored crystals with, m.p. = 131°-133°C and consistent NMR (270 MHz, CDCl₃) spectral data.

Microanalysis Calcd for C₂₁H₃₄N₂O₃: C, 69.58;
H, 9.45; N, 7.73
Found: C, 69.60; H, 9.40; N, 7.63

Example 9

4-[(4-Decylbenzoyl)hydroxyamino]butanoic acid

A. (Z)-4-[[4-(1-Decenyl)benzoyl]benzyl- oxyamino]butanoic acid

To a magnetically stirred solution of the benzoic acid (prepared as in Example 1 Part C) (1.97 g, 7.57 mM) in dry acetone (20 ml) at -10°C (dry ice/acetone) and under argon was added isobutylchloroformate (1.1 ml, 8.48 mM) followed by Et₃N (1.2 ml, 7.57 mM). This was stirred for 30 minutes at -10°C, then filtered into a cooled solution (-15°C) of the hydrolysis product prepared as described in Example 4 Part D(1). The resulting mixture was stirred for 30 minutes at -10°C (dry ice/acetone) then allowed to warm to room temperature and stirred overnight. The reaction mixture was then partitioned between EtOAc and 5% KHSO₄. The organic layer was washed with brine, dried over anhydrous Na₂SO₄ and concentrated in vacuo to a yellow oil (5.0 g). A flash chromatography on LPS-1 silica gel eluting with (7:1) CH₂Cl₂-acetone yielded 680 mg (20%) of

5 B. 4-[(4-Decylbenzoyl)hydroxyamino]-
butanoic acid

Microanalysis Calcd for $C_{21}H_{33}NO_4$: C, 69.39;
H, 9.15; N, 3.85

Example 10

30 A. (Z)-5-[[4-(1-Decenyl)benzoyl]benzyl-
oxyamino]pentanoic acid, ethyl ester

Prewashed NaH (51 mg, 2.11 mM, 1.1 eq.) was added to a solution of the hydroxamate prepared as described in Example 1 Part D (700 mg, 1.92 mM) in

dry toluene (10 ml) and the mixture stirred for 20 minutes at room temperature under argon. Ethyl-5-iodovalerate (1.48 g, 5.76 mM, 3 eq.) was added and the mixture refluxed overnight. The mixture was then partitioned between 5% KHSO_4 and EtOAc, the organic layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated to a yellow oil. The remaining starting material was removed by chromatographing on neutral alumina (act. = 1) eluting with (1:1) petroleum-ether. Product fractions were evaporated, then flash chromatographed on Whatman LPS-1 silica gel eluting with (3:2) petroleum ether-ether. Product fractions were evaporated to give 760 mg (80%) of the title N-alkylated product as a clear oil with consistent NMR (CDCl_3 , 270MHz) spectral data. TLC (1:1) petroleum ether-Et₂O, R_f = 0.42 UV and PMA.

B. 5-[(4-Decylbenzoyl)hydroxyamino]-
pentanoic acid, ethyl ester

Argon was bubbled through a solution of the title A benzylhydroxamate (750 mg) in methanol (10 ml) for 5 minutes, then 20% palladium hydroxide on carbon (90 mg, 12% by weight) was added and the mixture stirred under H_2 for 1 hour. The mixture was filtered through Celite, evaporated, taken up in ethyl acetate, filtered through powdered anhydrous MgSO_4 and evaporated to give 590 mg (96%) of the desired title hydroxamic acid as an off-white solid with consistent NMR (60MHz, CDCl_3) spectral data. TLC (1:1) EtOAc-Hex, R_f =0.68, UV + PMA.

C. 5-[(4-Decylbenzoyl)hydroxyamino]-
pentanoic acid

To a solution of the title B ethyl ester (590 mg, 1.45 mM) in dioxane (8 ml) was added 1.0 N LiOH (2.9 ml, 2 eq.) and the mixture stirred under argon at room temperature for 40 minutes. The mixture was then partitioned between 5% KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an off-white solid. One recrystallization from EtOAc-Hex gave 439 mg (80%, analytical) of the desired title acid as light purple crystals with consistent NMR(CDCl₃, 270MHz) spectral data. TLC neat EtOAc, R_f=0.44, UV + PMA.

Microanalysis Calcd for C₂₂H₃₅NO₄: C, 69.99;
H, 9.35; N, 3.71
Found: C, 69.94; H, 9.33; N, 3.80

Example 11

(4-Decyl-N-hydroxybenzamido)acetic acid

A. 4-Decyl benzoic acid

Argon was bubbled through a solution of the unsaturated acid prepared in Example 1 Part C (1.0 g) in CH₃OH (20 ml) for 5 minutes. 10% Palladium on carbon was added and the mix was shaken on a Parr apparatus for 4 hours under H₂. The mixture was filtered through Celite and evaporated to give 960 mg (97%) of the desired title saturated acid as a white solid with consistent NMR (CDCl₃, 60MHz) spectral data. TLC (1:1) EtOAc-Hex, R_f=0.75, UV and PMA.

B. 4-Decyl-N-benzyloxybenzamide

To a solution of the title A acid (900 mg, 3.43 mM) in dry CH_2Cl_2 (15 ml) was added 1-hydroxybenzotriazole (557 mg, 4.12 mM, 1.2 eq.) and N,N'-dicyclohexylcarbodiimide (850 mg, 4.12 mM, 1.2 eq.) and the mixture stirred at room temperature under argon for 1 hour. Triethylamine (1.20 ml, 8.58 mM, 2.5 eq.) and O-benzylhydroxylamine hydrochloride (1.37 g, 8.58 mM, 2.5 eq.) were then added and the mixture stirred for 3 hours at room temperature. The mixture was filtered, evaporated, taken up in ethyl acetate and washed successively with 5% KHSO_4 and brine then dried over anhydrous Na_2SO_4 and evaporated to a white solid. Crude solid was flash chromatographed on Whatman LPS-1 silica gel eluting with (9:1) hexane-EtOAc. Product containing fractions were evaporated to give 1.11 g (87%) of the desired title benzylhydroxamate as white plates, m.p. = 82°-83°C, after recrystallization from EtOAc-hexane. TLC (1:1) EtOAc-Hex, R_f =0.59, UV and PMA.

Microanalysis Calcd for $\text{C}_{24}\text{H}_{33}\text{NO}_2$: C, 78.44;
H, 9.05; N, 3.81

Found: C, 78.32; H, 9.16; N, 3.75

C. N-(3-Prop-1-enyl)-4-decyl-N-benzyloxy benzamide

To a solution of the title B benzylhydroxamate (500 mg, 1.36 mM) in dry toluene (6 ml) was added prewashed NaH (36 mg, 1.50 mM, 1.1 eq.) and the solution stirred at room temperature for 20 minutes before adding allyl bromide (294 μl , 3.4

mM, 2.5 eq.) and refluxing overnight. The mixture was cooled, partitioned between 5% KHSO_4 and EtOAc, the organic layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated to a yellow oil. 5 Crude oil was chromatographed on neutral alumina (act.=1) eluting with (1:1) petroleum ether-ether. Product fractions were evaporated to give 510 mg (92%) of the title N-alkylated product as a light yellow oil with consistent NMR (CDCl_3 , 270 MHz) 10 spectral data. TLC (1:1) petroleum ether-ether, R_f =0.59, UV and PMA.

D. (4-Decyl-N-benzyloxybenzamido)acetic
acid, methyl ester

15 The title C N-alkylbenzylhydroxamate (490 mg, 1.202 mM) was dissolved in EtOAc, (6 ml) cooled to -78°C and purged with O_2 before bubbling ozone through the solution until a pale blue color persisted. Excess ozone was purged with bubbling 20 N_2 , then the ozonide solution was treated with Jones reagent (1.0 ml) at -78°C . The mixture was allowed to warm to room temperature, diluted with EtOAc and the organic phase washed successively with H_2O and brine, then dried over anhydrous 25 Na_2SO_4 and evaporated to a crude oil. TLC (95:5) CH_2Cl_2 - CH_3OH , R_f = acid 0.21, UV and PMA.

The crude oil was dissolved in Et_2O (10 ml), cooled to 0°C (ice bath) and treated with an ethereal solution of diazomethane. The mixture was 30 evaporated, and chromatographed on Whatman LPS-1 silica gel eluting with (9:1) Hex-EtOAc. Product fractions were evaporated to give 288 mg (55% for overall sequence) of the desired title methyl

ester as a clear oil with consistent NMR(CDCl_3 , 270MHz) spectral data. TLC (9:1) Hex-EtOAc, R_f CH_3 ester = 0.10, UV and PMA.

5 E. (4-Decyl-N-hydroxybenzamido)acetic acid, methyl ester

Argon was bubbled through a solution of the title D benzylhydroxamate (270 mg) in CH_3OH (8 ml) for 5 minutes, then 20% palladium hydroxide on
10 carbon (32 mg, 12% by weight) was added and the mixture stirred for 1 hour under H_2 . The mixture was filtered through Celite, evaporated, taken up in EtOAc, filtered through anhydrous MgSO_4 and evaporated to give 213 mg (99%) of the title E
15 hydroxamic acid as a violet, low-melting, crystalline solid. TLC (1:1) EtOAc-Hex, R_f = 0.58 UV and PMA.

F. (4-Decyl-N-hydroxybenzamide)acetic acid
20 To a solution of the title E methyl ester (210 mg, 0.578 mM) was dissolved in dioxane (6 ml) was added 1.0N LiOH (1.16 ml, 1.16 mM, 2. eq.) and the mixture stirred for 20 minutes at room temperature under argon. The mixture was parti-
25 tioned between 5% KHSO_4 and EtOAc, the organic phase washed with brine, dried over anhydrous Na_2SO_4 and evaporated to an off-white solid. One recrystallization from EtOAc-Hex gave 166 mg (82%) of the desired title acid as white crystals with
30 consistent NMR (270MHz, CDCl_3) spectral data. TLC (9:1) CH_2Cl_2 - CH_3OH , R_f 0.10, UV and PMA. m.p. 128°-130°C.

Microanalysis Calcd for $C_{19}H_{29}NO_4$: C, 68.03;

H, 8.71; N, 4.18

Found: C, 67.88; H, 8.89; N, 4.19

5

Example 12

4-[[3-(1-Decenyl)benzoyl]hydroxyamino]butanoic
acid

A. (Z)-3-(1-Decenyl)-N-(tetrahydropyran-
2-yloxy)benzamide

10

To a solution of the benzoic acid prepared
as described in Example 4 Part C (800 mg, 3.07 mM)
in dry CH_2Cl_2 (12 ml) was added 1-hydroxybenzo-
triazole (497 mg, 3.68 mM) and DCC (759 mg, 3.68
mM) and the mixture stirred at room temperature
15 under argon for 1 hour. O-Tetrahydropyran-2-
ylhydroxylamine prepared as described in Example 2
Part A (719 mg, 6.14 mM, 2 eq.) was added, the
mixture stirred for 3 hours at room temperature,
then filtered and evaporated. The residue was
20 taken up in EtOAc, filtered, evaporated and
chromatographed on LPS-1 silica gel eluting
successively with (7:3)+(6:4) petroleum ether-
ether. Product fractions were evaporated to give
764 mg (69%) of the desired title O-THP hydroxamate
25 as a light yellow oil with consistent NMR (270 MHz,
 $CDCl_3$) spectral data. TLC (1:1) Et_2O -petroleum
ether, R_F =0.30, UV + PMA.

30

B. (Z)-4-[[3-(1-Decenyl)benzoyl]tetrahydro-
pyran-2-yloxyamino]butanoic acid,
ethyl ester

Prewashed NaH (53 mg, 2.21 mM, 1.1 eq.) was
added to a solution of the title A O-THP

hydroxamate (724 mg, 2.01 mM) in dry toluene (10 ml) and the mixture stirred for 30 minutes at room temperature under argon. Ethyl-4-iodobutyrate, (1.46 g, 6.03 mM, 3 eq.) was added, the mixture
5 refluxed overnight, then partitioned between 5% KHSO_4 and ethyl acetate. The organic phase was washed with brine, dried over anhydrous Na_2SO_4 and evaporated to an oil. The crude oil was purified by flash chromatography on LPS-1 silica gel eluting
10 with a (95:5) Hex-Acetone mixture. Product fractions were evaporated to give 637 mg (67%) of the desired title N-alkylated product as a light yellow oil with consistent NMR (270 MHz, CDCl_3) spectral data. TLC (8:2) Hex-Acetone, $R_f = 0.47$,
15 UV + PMA.

C. 4-[[3-(1-Decenyl)benzoyl]hydroxyamino]-
butanoic acid, ethyl ester

A stirred solution of the title B O-THP
20 hydroxamate (617 mg) in (3:2:2) HOAc:THF: H_2O (5 ml) was heated at 55°C overnight under argon. The mixture was then diluted with EtOAc, the organic phase washed successively with saturated NaHCO_3 and brine, dried over anhydrous Na_2SO_4 and
25 evaporated to give 514 mg of the crude title hydroxamic acid as a light brown oil. TLC (1:1) EtOAc-Hex, $R_f = 0.52$ (with streaking to baseline), UV + PMA. Compound was subsequently hydrolyzed without further purification.

D. 4-[[3-(1-Decenyl)benzoyl]hydroxyamino]-
butanoic acid

A solution of the title C ethyl ester (498
mg, 1.26 mM) in dioxane (6 ml) was treated with
5 1.0 N LiOH (2.52 ml, 2 eq.) and the mixture
stirred for 1.5 hours at room temperature under
argon. The mixture was then partitioned between
5% KHSO₄ and EtOAc, the organic phase washed with
brine, dried over anhydrous Na₂SO₄ and evaporated
10 to an oil. The oil crystallized from hexane with
cooling and scratching and was then recrystallized
from EtOAc-Hex to give 380 mg (81% analytical
yield for last 2 steps) of the desired title
hydroxamic acid as straw colored crystals with
15 m.p.=71°-73°C and with consistent NMR (270 MHz,
CDCl₃) spectral data. TLC (9:1) CH₂Cl₂-CH₃OH,
R_f=0.50, UV + PMA.

Microanalysis Calcd for C₂₁H₃₁NO₄: C, 69.77;
20 H, 8.64, N, 3.88
Found: C, 69.56; H, 8.71; N, 3.76

Example 13

3-Decyl-N-hydroxy-N-methylbenzamide

25 Following the procedure of Example 1 except
substituting m-formylmethylbenzoate for
p-formylmethylbenzoate in Part B, the title
compound is obtained.

Example 14

2-Decyl-N-hydroxy-N-methylbenzamide

30 Following the procedure of Example 1 except
substituting o-formylmethylbenzoate for

p-formylmethylbenzoate in Part B, the title compound is obtained.

Example 15

5 4-Decyl-N-hydroxy-N-ethylbenzamide

Following the procedure of Example 1 except substituting ethyl iodide for methyl iodide, the title compound is obtained.

10 Example 16

4-Decyl-N-hydroxy-N-benzylbenzamide

Following the procedure of Example 1 except substituting benzyl bromide for methyl iodide, the title compound is obtained.

15 Example 17

4-Decyl-N-hydroxy-N-propylbenzamide

Following the procedure of Example 1 except substituting propyl iodide for methyl iodide, the title compound is obtained.

20 Example 18

4-Decyl-N-hydroxy-N-butylbenzamide

Following the procedure of Example 1 except substituting butyl iodide for methyl iodide, the title compound is obtained.

Example 19

30 4-Decyl-N-hydroxy-N-i-butylbenzamide

Following the procedure of Example 1 except substituting i-butyl iodide for methyl iodide, the title compound is obtained.

Example 204-Decyl-N-hydroxy-N-pentylbenzamide

Following the procedure of Example 1 except substituting pentyl iodide for methyl iodide, the title compound is obtained.

Example 214-Decyl-N-hydroxy-N-hexylbenzamide

Following the procedure of Example 1 except substituting hexyl iodide for methyl iodide, the title compound is obtained.

Example 224-Decyl-N-hydroxy-N-phenethylbenzamide

Following the procedure of Example 1 except substituting phenethyl bromide for methyl iodide, the title compound is obtained.

Example 234-Decyl-N-hydroxy-N-octylbenzamide

Following the procedure of Example 1 except substituting octyl iodide for methyl iodide, the title compound is obtained.

Example 244-Decyl-N-hydroxy-benzamide

Following the procedure of Example 1 except eliminating Step E, the title product is obtained.

Example 254-Decyl-N-methoxy-N-methylbenzamide

Following the procedure of Example 1 except substituting methoxyamine hydrochloride for benzyl-

hydroxyl amine hydrochloride in Part D, the title compound is obtained.

Example 26

5 4-Decyl-N-ethoxy-N-ethylbenzamide

Following the procedure of Example 1 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and substituting ethyl iodide for methyl iodide in Part
10 E, the title compound is obtained.

Example 27

4-Decyl-N-propoxy-N-butylbenzamide

Following the procedure of Example 1 except
15 substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and substituting butyl iodide for methyl iodide in Part E, the title compound is obtained.

Example 28

20 4-Decyl-N-pentoxo-N-ethylbenzamide

Following the procedure of Example 1 except substituting pentoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and
25 substituting ethyl iodide for methyl iodide in Part E, the title compound is obtained.

Example 29

4-Decyl-N-hexyloxy-N-propylbenzamide

30 Following the procedure of Example 1 except substituting hexyloxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and

substituting propyl iodide for methyl iodide in Part E, the title compound is obtained.

Example 30

5 4-Decyl-N-ethoxy-N-benzylbenzamide

Following the procedure of Example 1 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and substituting benzyl iodide for methyl iodide in
10 Part E, the title compound is obtained.

Example 31

4-Decyl-N-propoxy-N-phenethylbenzamide

Following the procedure of Example 1 except
15 substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and substituting phenethyl iodide for methyl iodide in Part E, the title compound is obtained.

20 Example 32

4-Decyl-N-butoxy-N-pentylbenzamide

Following the procedure of Example 1 except substituting butoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and
25 substituting n-pentyl iodide for methyl iodide in Part E, the title compound is obtained.

Example 33

4-Decyl-N-ethoxybenzamide

30 Following the procedure of Example 1 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D

and eliminating Step E, the title compound is obtained.

Example 34

5 4-Decyl-N-propoxybenzamide

Following the procedure of Example 1 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D and eliminating Step E, the title compound is
10 obtained.

Example 35

4-(1-Decenyl)-N-methoxy-N-methylbenzamide

Following the procedure of Example 1 except
15 substituting methoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D, and eliminating Step F, the title compound is obtained.

Example 36

20 4-(1-Decenyl)-N-ethoxy-N-ethylbenzamide

Following the procedure of Example 1 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D, substituting ethyl iodide for methyl iodide in Part
25 E, and eliminating Step F, the title compound is obtained.

Example 37

4-(1-Decenyl)-N-propoxy-N-butylbenzamide

30 Following the procedure of Example 1 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D, substituting butyl iodide for methyl iodide in Part

E, and eliminating Step F, the title compound is obtained.

Example 38

5 4-(1-Decenyl)-N-pentoxo-N-ethylbenzamide

Following the procedure of Example 1 except substituting pentoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D, substituting ethyl iodide for methyl iodide in Part
10 E, and eliminating Step F, the title compound is obtained.

Example 39

4-(1-Decenyl)-N-hexyloxy-N-n-propylbenzamide

15 Following the procedure of Example 1 except substituting hexyloxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D, substituting propyl iodide for methyl iodide in Part E, and eliminating Step F, the title compound
20 is obtained.

Example 40

4-(1-Decenyl)-N-ethoxy-N-benzylbenzamide

Following the procedure of Example 1 except
25 substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part D, substituting benzyl iodide for methyl iodide in Part E, and eliminating Step F, the title compound
is obtained.

Example 41

4-(1-Decenyl)-N-methoxy-N-phenethylbenzamide

Following the procedure of Example 1 except substituting methoxylamine hydrochloride for
5 benzylhydroxylamine hydrochloride in Part D, substituting phenethyl iodide for methyl iodide in Part E, and eliminating Step F, the title compound is obtained.

10

Example 42

4-(1-Decenyl)-N-methoxy-N-ethylbenzamide

Following the procedure of Example 1 except substituting methoxylamine hydrochloride for
benzylhydroxylamine hydrochloride in Part D,
15 substituting ethyl iodide for methyl iodide in Part E, and eliminating Step F, the title compound is obtained.

Example 43

20 4-(1-Decenyl)-N-ethoxybenzamide

Following the procedure of Example 1 except substituting ethoxylamine hydrochloride for
benzylhydroxylamine hydrochloride in Part D, and
eliminating Steps E and F, the title compound is
25 obtained.

Example 44

4-Undecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Example 1 except
30 substituting 1-bromodecane for 1-bromononane in Part A, the title compound is obtained.

Example 454-Hexyl-N-hydroxy-N-methylbenzamide

Following the procedure of Example 1 except substituting 1-bromopentane for 1-bromononane, the title compound is obtained.

Example 464-Heptyl-N-hydroxy-N-methylbenzamide

Following the procedure of Example 1 except substituting 1-bromohexane for 1-bromononane, the title compound is obtained.

Example 474-Octyl-N-hydroxy-N-methylbenzamide

Following the procedure of Example 1 except substituting 1-bromoheptane for 1-bromononane, the title compound is obtained.

Example 484-Nonyl-N-hydroxy-N-methylbenzamide

Following the procedure of Example 1 except substituting 1-bromooctane for 1-bromononane, the title compound is obtained.

Example 494-Dodecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Example 1 except substituting 1-bromoundecane for 1-bromononane, the title compound is obtained.

Example 504-Pentadecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Example 1 except substituting 1-bromotetradecane for 1-bromononane, the title compound is obtained.

Example 513-Octyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and 13 except substituting 1-bromoheptane for 1-bromononane, the title compound is obtained.

Example 523-Heptyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and 13 except substituting 1-bromohexane for 1-bromononane, the title compound is obtained.

Example 533-Dodecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and 13 except substituting 1-bromoundecane for 1-bromononane, the title compound is obtained.

Example 543-Octadecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and 13 except substituting 1-bromoheptadecane for 1-bromononane, the title compound is obtained.

Example 553-Tetradecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and
13 except substituting 1-bromotridecane for
5 1-bromononane, the title compound is obtained.

Example 563-Hexyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and
10 13 except substituting 1-bromopentane for
1-bromononane, the title compound is obtained.

Example 572-Hexyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and
15 14 except substituting 1-bromopentane for
1-bromononane, the title compound is obtained.

Example 5820 2-Octyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and
14 except substituting 1-bromoheptane for
1-bromononane, the title compound is obtained.

Example 5925 2-Undecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and
14 except substituting 1-bromodecane for
1-bromononane, the title compound is obtained.

Example 602-Pentadecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and 14 except substituting 1-bromotetradecane for 1-bromononane, the title compound is obtained.

Example 612-Heptadecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and 14 except substituting 1-bromohexadecane for 1-bromononane, the title compound is obtained.

Example 622-Nonadecyl-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 1 and 14 except substituting 1-bromooctadecane for 1-bromononane, the title compound is obtained.

Example 634-(1-Hexenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 2 except substituting 1-bromopentane for 1-bromononane in Part A and substituting methyl iodide for ethyl-4-iodobutyrate in Part C, the title compound is obtained.

Example 643-(1-Heptenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 2 and 13 except substituting 1-bromohexane for 1-bromononane and substituting methyl iodide for ethyl-4-iodobutyrate, the title compound is obtained.

Example 653-(1-Nonenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 12 except substituting 1-bromooctane for 1-bromononane and methyl iodide for ethyl-4-iodobutyrate in Part B, the title compound is obtained.

Example 663-(1-Undecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 12 except substituting 1-bromodecane for 1-bromononane and methyl iodide for ethyl-4-iodobutyrate in Part B, the title compound is obtained.

Example 673-(1-Tridecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 12 except substituting 1-bromododecane for 1-bromononane and methyl iodide for ethyl-4-iodobutyrate in Part B, the title compound is obtained.

Example 683-(1-Pentadecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 12 except substituting 1-bromotetradecane for 1-bromononane and methyl iodide for ethyl-4-iodobutyrate in Part B, the title compound is obtained.

Example 693-(1-Heptenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 12 except substituting 1-bromohexane for 1-bromononane and

methyl iodide for ethyl-4-iodobutyrate in Part B,
the title compound is obtained.

Example 70

5 4-(1-Octenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 2 except
substituting 1-bromoheptane for 1-bromononane and
methyl iodide for ethyl 4-iodobutyrate in Part C,
the title compound is obtained.

10

Example 71

4-(1-Nonenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example
13 except substituting 1-bromooctane for
15 1-bromononane and methyl iodide for ethyl
4-iodobutyrate in Part C, the title compound is
obtained.

Example 72

20 4-(1-Dodecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 2 except
substituting 1-bromoundecane for 1-bromononane and
methyl iodide for ethyl 4-iodobutyrate in Part C,
the title compound is obtained.

25

Example 73

4-(1-Tetradecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 2 except
substituting 1-bromotridecane for 1-bromononane and
30 methyl iodide for ethyl 4-iodobutyrate in Part C,
the title compound is obtained.

Example 744-(1-Hexadecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Example 2 except substituting 1-bromopentadecane for 1-bromononane and methyl iodide for ethyl 4-iodobutyrate in Part C, the title compound is obtained.

Example 752-(1-Eicosenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 2 and 14 except substituting 1-bromononadecane for 1-bromononane and methyl iodide for ethyl 4-iodobutyrate in Part C, the title compound is obtained.

Example 762-(1-Octadecyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 2 and 14 except substituting 1-bromoheptadecane for 1-bromononane and methyl iodide for ethyl 4-iodobutyrate in Part C, the title compound is obtained.

Example 772-(1-Hexadecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 2 and 14 except substituting 1-bromopentadecane for 1-bromononane and methyl iodide for ethyl 4-iodobutyrate in Part C, the title compound is obtained.

Example 782-(1-Tetradecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 2 and 14 except substituting 1-bromotridecane for 1-bromononane and methyl iodide for ethyl 4-iodobutyrate in Part C, the title compound is obtained.

Example 7910 2-(1-Dodecenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 2 and 14 except substituting 1-bromoundecane for 1-bromononane and methyl iodide for ethyl 4-iodobutyrate in Part C, the title compound is obtained.

Example 802-(1-Hexenyl)-N-hydroxy-N-methylbenzamide

Following the procedure of Examples 2 and 14 except substituting 1-bromopentane for 1-bromononane and methyl iodide for ethyl 4-iodobutyrate in Part C, the title compound is obtained.

25 Example 814-[[4-Decylbenzoyl]hydroxyamino]butanoic acid

Following the procedure of Example 1 except substituting ethyl-4-iodobutyrate for methyl iodide, the title compound is obtained.

Example 825-[[3-Decylbenzoyl]hydroxyamino]pentanoic acid

Following the procedure of Examples 1 and 13 except substituting ethyl-5-iodovalerate for methyl iodide, the title compound is obtained.

Example 835-[[2-Decylbenzoyl]hydroxyamino]pentanoic acid

Following the procedure of Examples 1 and 14 except substituting ethyl-5-iodovalerate for methyl iodide, the title compound is obtained.

Example 845-[[4-(1-Decenyl)benzoyl]hydroxyamino]pentanoic acid

Following the procedure of Example 2 except substituting ethyl-5-iodovalerate for ethyl-4-iodobutyrate, the title compound is obtained.

Example 855-[[4-(1-Heptenyl)benzoyl]methoxyamino]pentanoic acid

Following the procedure of Example 7 except substituting 1-bromohexane for 1-bromononane, and ethyl-5-iodovalerate for ethyl-4-iodobutyrate and eliminating the addition of dicyclohexylamine, the title compound is obtained.

Example 864-[[4-(1-Nonenyl)benzoyl]methoxyamino]butanoic acid

Following the procedure of Example 7 except substituting 1-bromooctan for 1-bromononane, and

eliminating the addition of dicyclohexylamine, the title compound is obtained.

Example 87

5 5-[[4-(1-Undecenyl)benzoyl]methoxyamino]pentanoic
acid

Following the procedure of Example 7 except substituting 1-bromodecane for 1-bromononane, and ethyl-5 iodovalerate for ethyl-4-iodobutyrate and
10 eliminating the addition of dicyclohexylamine, the title compound is obtained.

Example 88

15 4-[[4-(1-Tridecyl)benzoyl]methoxyamino]butanoic
acid

Following the procedure of Example 7 except substituting 1-bromododecane for 1-bromononane, and eliminating the addition of dicyclohexylamine, the title compound is obtained.

20

Example 89

3-[[4-(1-Hexenyl)benzoyl]ethoxyamino]pentanoic
acid

Following the procedure of Example 7 except substituting 1-bromopentane for 1-bromononane, ethoxylamine hydrochloride for methoxylamine hydrochloride and ethyl-3 iodovalerate for ethyl-4-iodobutyrate, and eliminating the addition of dicyclohexylamine, the title compound is
25 obtained.
30

Example 90

5-[[3-(1-Tetradecenyl)benzoyl]propoxyamino]-
pentanoic acid

Following the procedure of Examples 7 and
13 except substituting 1-bromotridecane for
1-bromononane, propoxylamine hydrochloride for
methoxylamine hydrochloride, and ethyl-5 iodo-
valerate for ethyl-4-iodobutyrate and eliminating
the addition of dicyclohexylamine, the title
compound is obtained.

Example 91

4-[[4-(1-Octadecenyl)benzoyl]hexyloxyamino]-
butanoic acid

Following the procedure of Example 7 except
substituting 1-bromoheptadecane for 1-bromononane
and hexyloxylamine hydrochloride for methoxylamine
hydrochloride, and eliminating the addition of
dicyclohexylamine, the title compound is obtained.

Example 92

4-[[2-(1-Octenyl)benzoyl]pentyloxyamino]-
butanoic acid

Following the procedure of Examples 7 and
14 except substituting 1-bromoheptane for
1-bromononane, pentyloxylamine hydrochloride for
methoxylamine hydrochloride, and eliminating the
addition of dicyclohexylamine, the title compound
is obtained.

Example 93(4-Dodecyl-N-hydroxybenzamido)acetic acid

Following the procedure of Example 11 except substituting 1-bromoundecane for 1-bromononane, the title compound is obtained.

Example 94(4-Hexyl-N-hydroxybenzamido)acetic acid

Following the procedure of Example 11 except substituting 1-bromopentane for 1-bromononane, the title compound is obtained.

Example 95(3-Nonyl-N-hydroxybenzamido)acetic acid

Following the procedure of Examples 11 and 13 except substituting 1-bromooctane for 1-bromononane, the title compound is obtained.

Example 96(4-Tetradecyl-N-hydroxybenzamido)acetic acid

Following the procedure of Example 11 except substituting 1-bromotridecane for 1-bromononane, the title compound is obtained.

Example 97(3-Pentadecyl-N-methoxybenzamido)acetic acid

Following the procedure of Examples 11 and 13, except substituting 1-bromotetradecane for 1-bromononane and methoxylamine hydrochloride for benzyloxylamine hydrochloride, the title compound is obtained.

Example 98(2-Nonadecyl-N-propoxybenzamido)acetic acid

Following the procedure of Examples 11 and 14, except substituting 1-bromooctadecane for 1-bromononane and propoxylamine hydrochloride for benzyloxylamine hydrochloride, the title compound is obtained.

Example 99(4-Heptyl-N-hydroxylbenzamide)acetic acid

Following the procedure of Example 11, except substituting 1-bromohexane for 1-bromononane, the title compound is obtained.

Example 100(3-Decyl-N-hexyloxybenzamido)acetic acid

Following the procedure of Examples 11 and 13, except substituting hexyloxylamine hydrochloride for benzyloxylamine hydrochloride, the title compound is obtained.

Example 101(2-Decyl-N-heptyloxybenzamido)acetic acid

Following the procedure of Examples 11 and 14, except substituting heptyloxylamine hydrochloride for benzyloxylamine hydrochloride, the title compound is obtained.

Example 102N-(4-Amino-4-oxobutyl)-4-octyl-N-methoxy benzamide

Following the procedure of Example 8 except substituting 1-bromoheptane for 1-bromononane and

methoxylamine hydrochloride for benzyloxylamine hydrochloride, the title compound is obtained.

Example 103

5 N-(4-Amino-4-oxobutyl)-4-tridecyl-N-ethoxy benzamide

Following the procedure of Example 8 except substituting 1-bromododecane for 1-bromononane and ethoxylamine hydrochloride for benzyloxylamine hydrochloride, the title compound is obtained.

10

Example 104

N-(4-Amino-4-oxobutyl)-4-decyl-N-methoxy benzamide

Following the procedure of Example 8 except substituting methoxylamine hydrochloride for benzyloxylamine hydrochloride, the title compound is obtained.

15

Example 105

N-(4-Amino-4-oxobutyl)-4-undecyl-N-hydroxy benzamide

Following the procedure of Example 8 except substituting 1-bromodecane for 1-bromononane, the title compound is obtained.

20

Example 106

25 N-(5-Amino-5-oxopentyl)-2-octyl-N-ethoxy benzamide

Following the procedure of Examples 8 and 14 except substituting 1-bromoheptane for 1-bromononane, ethoxylamine hydrochloride for benzyloxylamine hydrochloride, and ethyl 3-iodovalerate for ethyl-4-iodobutyrate, the title compound is obtained.

30

Example 107

N-(4-N-Ethylamino-4-oxobutyl)-3-tetradecyl-N-hydroxy benzamide

Following the procedure of Examples 8 and 13 except substituting 1-bromotridecane for 1-bromononane, and ethylamine for ammonium hydroxide, the title compound is obtained.

Example 108

N-(4-Amino-4-oxobutyl)-4-nonadecyl-N-hydroxy benzamide

Following the procedure of Example 8 except substituting 1-bromooctadecane for 1-bromononane, the title compound is obtained.

Example 109

(Z)-4-(1-Decenyl)-N-hydroxybenzamide

To a solution of compound prepared as described in Example 2 Part B (300 mg, 0.83 mmol) in 6 ml of CH_3OH under argon was added pyridinium 4-toluenesulfonate (210 mg, 1.0 eq.). The mixture was heated to 55°C and stirred for 4 hours. The solution was diluted with ether and washed with $\frac{1}{2}$ saturated sodium chloride (20 ml) and brine (10 ml). The organic layer was dried over anhydrous MgSO_4 and reduced to yield a white solid. Recrystallization from hexane/EtOAc gave 200 mg (87%) of title compound as an off-white solid.

TLC (1:1) Hexane:EtOAc, $R_f = 0.23$, UV + PMA, product streaks to baseline.

Microanal calcd for $C_{17}H_{25}NO_2$: C, 74.14; H, 9.15;
N, 5.09

Found: C, 73.90; H, 9.27; N, 5.39

5

Example 110

(Z)-4-Decyl-N-hydroxybenzamide

Following the procedure of Example 1 Part F except substituting the Example 109 compound for the Example 1 Part E compound, the title compound is obtained.

10

Example 111

3-(1-Heptenyl)-N-hydroxybenzamide

Following the procedure of Examples 109 and 13 except substituting 1-bromohexane for 1-bromononane in Example 1, Part A, the title compound is obtained.

15

Example 112

4-(1-Tetradecenyl)-N-hydroxybenzamide

Following the procedure of Example 109 except substituting 1-bromotridecane for 1-bromononane in Example 1, Part A, the title compound is obtained.

20

25

Example 113

2-(1-Dodecenyl)-N-hydroxybenzamide

Following the procedure of Examples 109 and 14 except substituting 1-bromoundecane for 1-bromononane in Example 1, Part A, the title compound is obtained.

30

Example 1144-(1-Nonadecenyl)-N-hydroxybenzamide

Following the procedure of Example 109 except substituting 1-bromooctadecane for 1-bromononane in Example 1, Part A, the title compound is obtained.

Example 115N-Hydroxy-N-methyl-4-(4-phenylbutyl)benzamide10 A. 3-Phenylpropyl phosphonium bromide

A magnetically stirred suspension of 1-bromo-3-phenylpropane (Aldrich, 13.7 ml, 90 mmol) and triphenylphosphine (47.2 g, 180 mmole) was heated at 100°C (oil bath) for 2 hours. The resulting white solid was then cooled and triturated with ether (5X) to remove most of the unreacted triphenylphosphine, to give the title Wittig salt in 96% yield (wt. 40 g).

20 B. 4-(Phenyl-1-butenyl)benzoic acid, methyl ester

To a mixture of the Part A Wittig salt under argon (6.8 g, 1.2 eq.) dissolved in anhydrous THF (70 ml) cooled to -78°C was added n-BuLi (5.1 ml of a 2.4 M solution, 1.0 eq.). After stirring for 45 minutes, distilled hexamethylphosphorus (HMPA) (14.4 ml) was added to the orange mixture, turning it black. After stirring for an additional 15 minutes, p-formylmethylbenzoate (2.0 g, 12.2 mmole) in dry THF (10 ml) was added dropwise. After stirring for a two hour

period at -78°C , it was warmed to 0°C (ice bath) for 1 hour. H_2O was added and the mixture extracted with ethyl acetate. The organic layer was washed with saturated NH_4Cl (3X), brine, and then dried over anhydrous MgSO_4 . Concentration in vacuo gave a yellow oil which was flash chromatographed on LPS-1 silica gel, eluting with (95:5) Hex:EtOAc. Product containing fractions were concentrated in vacuo to yield the title Wittig product as a light yellow oil (2.72 g, 84%). TLC (95:5) Hex-EtOAc, $R_f=0.22$ UV + PMA.

C. 4-(4-Phenyl-1-butenyl)benzoic acid

To a stirred solution of the Part B methyl ester (2.72 g, 10.2 mmol) in CH_3OH (60 ml) and THF (10 ml) was added a 2.0 N NaOH solution (15.3 ml) and the mixture was refluxed under argon for 0.75 hour and quenched with 1 HCl (40.8 ml, 4.5 eq.). Concentration in vacuo to 1/3 volume left a white solid which was collected by filtration and recrystallized from hexane to yield title acid as a white solid, 2.2 g (86%). TLC (1:1) Hex-EtOAc, $R_f = 0.39$, UV + PMA.

D. 4-(4-Phenyl-1-butenyl)-N-(tetrahydropyran-2-yloxy)benzamide

To a 0°C solution of Part C acid (2.0 g, 7.9 mmol) in 40 ml of CH_2Cl_2 under argon was added N,N'-dicyclohexylcarbodiimide (DCC) (1.96 g, 1.2 eq.), 1-hydroxybenzotriazole (HOBt) (1.28 g, 1.2 eq.), tetrahydropyranyl hydroxylamine ($\text{H}_2\text{N-OHP}$) (1.86 g, 2.0 eq.), sequentially. The solution was all wed to warm to room temperature after 0.5 hour and then stirred under

argon for 3 hours. The solution was filtered, concentrated in vacuo, diluted with EtOAc, and refiltered. Concentration in vacuo gave a golden oil which was chromatographed on LPS-1 silica gel eluting with 7:3 hexane/EtOAc. Product containing fractions were concentrated in vacuo to yield title compound as a light yellow oil, wt. 2.8 g (~100%).

10 E. 4-(4-Phenyl-1-butenyl)-N-methyl-N-(tetrahydropyran-2-yloxy)benzamide

To a stirring solution of Part D compound (1.8 g, 5.1 mmol) under argon in 30 ml of dry toluene was added NaH (1.1 eq., 134 mg). The mixture was allowed to stir for 30 minutes and then CH₃I (0.95 ml, 3.0 eq.) was added. The mixture was heated to reflux and allowed to stir for 1 hour. The reaction was cooled and diluted with EtOAc and partitioned over 5% KHSO₄. The organic phase was washed with brine, dried over anhydrous Na₂SO₄ and evaporated to yield yellow oil which was chromatographed on LPS-1 silica gel eluting with (6:4) hexane:EtOAc. Product containing fractions were evaporated to give title compound (1.6 g, 87%) as a clear oil. TLC (1:1) hexane:EtOAc. R_f = 0.40, UV +PMA.

F. 4-(4-Phenylbutyl)-N-methyl-N-(tetrahydropyran-2-yloxy)benzamide

30 To a stirring solution of Part E compound (500 mg, 1.37 mmol) in 10 ml of CH₃OH was added rhodium/alumina (5%) (50 mg) under argon. Hydrogen gas was added and the reaction was allowed to stir

under H_2 (balloon) for 0.5 hour. The mixture was filtered (Millipore) and concentrated in vacuo to yield a clear oil which was carried directly on to the next step.

5

G. N-Hydroxy-N-methyl-4-(4-phenylbutyl)-benzamide

To a stirring solution of Part F compound (500 mg, 1.37 mmol) in 10 ml of CH_3OH under argon was added pyridinium-p-toluenesulfonate (344 mg, 1.0 eq.). The solution was heated to $60^\circ C$ in an oil bath for 5 hours, then diluted with EtOAc and washed with 10 ml of brine, and diluted with 10 ml of water. The organic layer was washed with brine (10 ml) and dried over Na_2SO_4 (anhydrous) and reduced in vacuo to yield an oil which was crystallized from hexane/EtOAc to give title product (325 mg) (84%) as a white solid with m.p. $62-63.5^\circ C$. TLC (1:1) hexane-EtOAc; $R_f = 0.28$, UV + PMA. Product streaks to baseline.

Anal Calcd for $C_{18}H_{21}NO_2$: C, 76.29; H, 7.47;
N, 4.94

Found: C, 76.20; H, 7.52; N, 4.68

25

Example 116

N-Hydroxy-N-methyl-4-(4-phenyl-1-butenyl)benzamide

To a solution of 4-(4-phenyl-1-butenyl)-N-methyl-N-(tetrahydropyran-2-yloxy)benzamide (prepared in Example 1 Part E) (500 mg, 1.37 mmol) in 12 ml of CH_3OH under argon was added pyridinium 4-toluenesulfonate (344 mg, 1.0 eq.). The mixture was heated to $55^\circ C$ and stirred for 2.5 hours. The

- solution was diluted with ether and washed with $\frac{1}{2}$ saturated sodium chloride (20 ml) and brine (10 ml). The organic layer was dried over anhydrous MgSO_4 and reduced to yield a light yellow oil
- 5 which was flash chromatographed on Merck silica gel, eluting with (7:3) Hex:EtOAc. Product containing fractions were concentrated in vacuo to yield title product, 426 mg (85%) as a golden oil.
- 10 TLC (1:1) Hexane:EtOAc, $R_f=0.18$, UV + PMA, product streaks to baseline. Trace $R_f=0.61$.

Anal Calcd for $\text{C}_{18}\text{H}_{19}\text{NO}_2$: C, 76.84; H, 6.81;
N, 4.98

- 15 Found: C, 76.80; H, 6.76; N, 4.71

Example 117

N-Hydroxy-N-Methyl[1,1'-biphenyl]-4-carboxamide

- A. 1,1'-Biphenylcarboxylic acid chloride
- 20 To a stirring solution of 1,1'-biphenyl-carboxylic acid (1.0 g, 4.6 mmol) in 10 ml of dry benzene, under argon was added oxalyl chloride (0.40 ml, 2.0 eq.). To this solution was added DMF
- 25 dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (two drops). The mixture was stirred for 1 hour, then reduced on the rotovap without heating. The crude product, white solid, was carried directly on to the next step.

B. N-Hydroxy-N-methyl[1,1'-biphenyl]-4-carboxamide

To a 0°C solution of N-methylhydroxylamine hydrochloride (771 mg, 2 eq.) in 7 ml of THF:H₂O (1:1) with triethylamine (1.43 ml, 3.0 eq.) was added Part A compound (~1.0 g, 4.6 mmol) in THF (5 ml). The solution was stirred for 2 hours at 0°C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with ether and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave a crystalline white solid which was isolated by filtration and washed with hexane, dried under vacuum over P₂O₅ to yield title product, 690 mg (66% from Part A compound), as a white solid with a m.p. of 133-134.5°C.

TLC (1:1) Hexane:EtOAc R_f=0.21 (trace R_f=0.5) UV + PMA. Product streaks to baseline.

Anal Calcd for C₁₄H₁₃NO₂: C, 73.99; H, 5.77;
N, 6.16

Found: C, 73.94; H, 5.93; N, 5.94

Example 118

N-Hydroxy-N-benzyl-4-(4-phenylbutyl)benzamide

Following the procedure of Example 115 except substituting benzyl bromide for methyl iodide in Example 115 Part E, the title compound is obtained.

Example 119N-Hydroxy-N-allyl-4-(4-phenylbutyl)benzamide

Following the procedure of Example 115 ,
except substituting allyl bromide for methyl
5 iodide in Example 115 Part E, the title compound is
obtained.

Example 120N-Hydroxy-N-phenyl[1,1'-biphenyl]-4-carboxamide

10 Following the procedure of Example 117
except substituting N-phenylhydroxylamine
hydrochloride for N-methylhydroxylamine
hydrochloride in Example 117 Part B, the title
compound is obtained.

15

Example 121N-Hydroxy-N-cyclohexyl[1,1'-biphenyl]-4-
carboxamide

20 Following the procedure of Example 117
except substituting N-cyclohexylhydroxylamine
hydrochloride for N-methylhydroxylamine
hydrochloride in Example 117 Part B, the title
compound is obtained.

25

Example 122N-Hydroxy-N-methyl-4-cyclohexylbenzamide

Following the procedure of Example 117
except substituting 4-cyclohexylbenzoic acid for
1,1'-biphenylcarboxylic acid in Part A, the title
30 compound is obtained.

Example 122a3-(4-Phenylbutyl)-N-hydroxy-N-methylbenzamide

5 Following the procedure of Example 115 except substituting m-formylmethylbenzoate for p-formylmethylbenzoate in Part B, the title compound is obtained.

Example 1232-(4-Phenylbutyl)-N-hydroxy-N-methylbenzamide

10 Following the procedure of Example 115 except substituting o-formylmethylbenzoate for p-formylmethylbenzoate in Part B, the title compound is obtained.

15

Example 1244-(4-Phenylbutyl)-N-hydroxy-N-ethylbenzamide

 Following the procedure of Example 115 except substituting ethyl iodide for methyl iodide, the title compound is obtained.

20

Example 1254-(4-Phenylbutyl)-N-hydroxy-N-benzylbenzamide

 Following the procedure of Example 115 except substituting benzyl bromide for methyl iodide, the title compound is obtained.

25

Example 1264-(4-Phenylbutyl)-N-hydroxy-N-propylbenzamide

30 Following the procedure of Example 115 except substituting propyl iodide for methyl iodide, the title compound is obtained.

Example 1274-(4-Phenyl-1-butenyl)-N-hydroxy-N-butylbenzamide

Following the procedure of Examples 115 and 116 except substituting butyl iodide for methyl iodide in Example 115 Part E, the title compound is obtained.

Example 128N-Hydroxy-N-i-butyl[1,1'-biphenyl]benzamide

Following the procedure of Example 117 except substituting i-butyl iodide for methyl iodide, the title compound is obtained.

Example 129N-Hydroxy-N-benzyl[1,1'-biphenyl]benzamide

Following the procedure of Example 117 except substituting benzyl bromide for methyl iodide, the title compound is obtained.

Example 130N-Hydroxy-N-hexyl-4-cyclohexylbenzamide

Following the procedure of Example 122 except substituting hexyl iodide for methyl iodide, the title compound is obtained.




Example 131N-Hydroxy-N-phenethyl-4-cyclohexylbenzamide

Following the procedure of Example 122 except substituting phenethyl bromide for methyl iodide, the title compound is obtained.

Examples 132 t 140






Following the procedure of Example 115,
except substituting for the 1-bromo-3-phenylpropane
the bromide shown in Table A, Column I, substitu-
5 ting for methyl iodide, the halide shown in Column
II, the product shown in Column III is obtained.



TABLE A

	<u>Column I</u>	<u>Column II</u>	<u>Column III</u>
	R^4Br	Hal R^{1a}	
<u>Ex.</u>			
<u>No.</u>	<u>R^4</u>	<u>Hal</u> <u>R^{1a}</u>	<u>R^4</u> <u>R^{1a}</u>
			
132.	C_4H_9	Br C_4H_9	as in Col. I as in Col. II
133.	C_3H_7	Br $C_6H_5CH_2$	
134.	C_7H_{15}	Br 	
135.	$C_6H_5(CH_2)_2$	Br $C_6H_5CH_2$	
136.	$C_6H_5CH_2$	Br C_2H_5	
137.	C_9H_{19}	I $C_6H_5CH_2$	
138.	$C_6H_5-(CH_2)_5$	I C_3H_7	
139.	CH_3	Br CH_3	
140.	C_2H_5	I C_5H_{11}	

Examples 141 to 147

Following the procedure of Example 115 Part A to E and Example 116 except substituting the, bromide shown in Column I of Table A for 1-bromo-3-phenylpropane used in Example 115 Part A and substituting the halide shown in Column II of Table A for methyl iodide used in Example 115 Part E, the following compounds are obtained.





Ex.No.



Examples 148 to 153

Following the procedure of Example 117 except substituting for N-methylhydroxylamine hydrochloride the hydroxylamine hydrochloride shown in column I of Table B set out below, the product of the invention shown in Column II is obtained.






TABLE B

		<u>Column I</u>	<u>Column II</u>
		$\begin{array}{c} \text{OH} \\ \diagup \\ \text{R}^1-\text{N} \\ \diagdown \\ \text{H} \end{array}$	
<u>Ex.No.</u>		<u>R¹</u>	<u>R¹</u>
			
148.		C ₃ H ₇	As per Column I
149.		C ₆ H ₅ (CH ₂) ₃	
150.		CH ₃ CH=CH-CH ₂ -	
151.		C ₅ H ₁₁	
152.			
153.			

Examples 154 to 159

Following the procedure of Example 122 except substituting for N-methylhydroxylamine hydrochloride the hydroxylamine hydrochloride shown in column I of Table C set out below, the product of the invention shown in Column II is obtained.

TABLE C

	Column I	Column II
		
Ex.No.	R ¹	R ¹
		 As per Column I
154.	C ₃ H ₇	
155.	C ₆ H ₅ (CH ₂) ₃	
156.	CH ₃ CH=CH-CH ₂ -	
157.	C ₅ H ₁₁	
158.		
159.		

Example 160N-Methoxy-N-methyl[1,1'-biphenyl]-4-carboxamide

To a stirring solution of N-hydroxy-N-methyl[1,1'-biphenyl]-4-carboxamide (prepared as described in Example 117) (1.13 g, 5 mmol) under argon in 30 ml of dry toluene is added NaH (0.137 g, 5.5 mmol). The mixture is allowed to stir for 30 minutes, then CH₃I (2.13 g, 15 mmol) is added. The mixture is heated to reflux and allowed to stir for 1 hour. The reaction is cooled and diluted with EtOAc and partitioned over 5% KHSO₄. The organic phase is washed with brine, dried over anhydrous Na₂SO₄ and evaporated to yield yellow

oil which is chromatographed on LPS-1 silica gel eluting with (6:4) hexane:EtOAc. Product containing fractions are evaporated to give title product.















5

Example 161 to 172

Following the procedure of Examples 1, 117 and 160 except substituting for the benzoic acid of Example 1, Part C, the acid shown in Column I of Table C set out below, substituting the hydroxyl-amine in Column II for N-methylhydroxyl amine, and substituting for methyl iodide, the alkyl halide set out in Column III, the product of the invention set out in Column IV is obtained.

10

TABLE C

Column I		Column II	Column III	Column IV		
			R^2-Br			
Ex. No.	R^3 (position)	R^1	R^2	R^3	R^1	R^2
						
161.	C_6H_5 (2)	C_3H_7	C_2H_5	as in	as in	as in
162.	C_6H_5 (3)	$C_6H_5(CH_2)_3$	C_3H_7	Col. I	Col. II	Col. III
163.	C_6H_5 (4)	$CH_3CH=CH-CH_2$	C_4H_9			
164.	C_6H_5 (2)	C_5H_{11}	C_5H_{11}			
165.	C_6H_5 (3)		CH_3			
166.	C_6H_5 (4)		CH_3			
167.	 (4)	C_3H_7	C_2H_5			
168.	 (3)	$C_6H_5(CH_2)_3$	C_3H_7			
169.	 (3)	$CH_3CH=CH-CH_2$	C_4H_9			
170.	 (2)	C_5H_{11}	C_5H_{11}			
171.	 (2)	$C_6H_5CH_2$	CH_3			
172.	 (4)	$C_6H_5CH_2$	CH_3			

Example 173N-(1,1-Dimethylethyl)-N-hydroxy-(4-phenylbutyl)-benzamide5 A. 4-(4-Phenyl-1-butenyl)benzoic acid, methyl ester

10 To a 0° solution of phenylpropyl triphenylphosphonium bromide (3.55 g, 1.25 eq) in 30 ml of dry THF under argon was added K-t-amylate (3.9 ml, 1.1 eq). After stirring for 30 minutes at 0°C then
15 allowing to warm to room temperature, a solution of 4-formylbenzoic acid methyl ester (1.0 g, 6.1 mmol) in ~8 ml of dry THF was added dropwise. This solution was stirred for 3 hours at room temperature, then diluted with ~1 ml of H₂O, and concentrated to remove most of the THF. EtOAc (~200 ml)
20 was added and the mixture was washed with H₂O, 1N HCl (2X) and brine. After drying over anhydrous MgSO₄, the solvent was removed in vacuo to yield a yellow oil which solidified soon after. Column
25 purification of this crude product was done on a 50 ~~mm~~ column on silica gel eluted with 95:5 hexane/EtOAc. Product containing fractions were combined to yield after concentration title compound, 1.5 g (93%) as a clear oil.

25 B. 4-(4-Phenylbutyl)benzoic acid, methyl ester

30 To a stirring solution of Part A ester (850 mg, 3.2 mmol) in 20 ml of CH₃OH was added Pd/C (5%) 85 mg under argon. Hydrogen gas was added and the reaction was allowed to stir under H₂ (balloon) for 1 hour. The mixture was filtered

(Millipore) and concentrated in vacuo to give title compound in the form of a clear oil, 850 mg (~100%).

5 C. 4-(4-Phenylbutyl)benzoic acid

A solution of Part B (850 mg; 3.2 mmol), 2N NaOH (4.8 ml, 3.0 eq) in 35 ml of CH₃OH/THF (5:1) was heated to reflux for 2½ hours. The solution was acidified with 1N HCl (15 ml). THF was removed in vacuo and a white solid was collected by filtration. This solid was dissolved in EtOAc and washed with ½ saturated brine, then brine. After drying over anhydrous MgSO₄, concentration gave title acid 680 mg as a white solid. The filtrate, from the original filtration, was extracted with EtOAc 2X (75 ml portions), washed with ½ saturated brine, then brine. Concentration after drying over anhydrous MgSO₄ gave title acid 800 mg, a total yield of 91%.

20

D. N-(1,1-Dimethylethyl)-N-hydroxy-4-(4-phenylbutyl)benzamide

To a stirring solution of Part C acid (350 mg, 1.4 mmol) in 10 ml of dry benzene under argon, was added oxalyl chloride (0.13 ml, 2.0 eq). To this solution was added DMF dropwise in 10 minute intervals, until no gas evolved and the solution turned slightly cloudy (two drops). The mixture was stirred for 1 hour, then reduced on the rotovap without heating. The crude product was dissolved in 5 ml of THF and added dropwise to a 0°C solution of N-t-butylhydroxylamine hydrochloride (325 mg, 2.0 eq) in 20 ml of THF:H₂O

30

(1:1) with triethylamine (0.59 ml, 3.0 eq). The solution was stirred for $\frac{1}{2}$ hour at 0°C, then allowed to warm to room temperature and stir for 4 hours. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave a yellow oil which gave a white solid (187 mg) with the addition of hexane. Recrystallization of this solid from hexane/EtOAc gave title product, 153 mg (35%).

TLC (1:1) Hexane:EtOAc R_f=0.41 UV + CeMo.
Product streaks to baseline.

Anal Calcd for C₂₁H₂₇NO₂: C, 77.50; H, 8.36;
N, 4.30
Found: C, 77.28; H, 8.43; N, 4.37

20

Example 174N-Hydroxy-N-phenyl-4-(4-phenylbutyl)benzamide

To a stirring solution of 4-(4-phenylbutyl)-benzoic acid (prepared as described in Example 173) (370 mg, 1.45 mmol) in 10 ml of dry benzene under argon, was added oxalyl chloride (0.14 ml, 2.0 eq.). To this solution was added DMF dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (2 drops). The mixture was stirred for 1 hour, then reduced on the rotovap without heating. The crude product was dissolved in 5 ml of THF and added dropwise to a 0°C solution of N-phenyl hydroxylamine (317 mg, 2.0 eq.) in 20 ml of THF:H₂O (1:1) with tri thyl-

amine (0.41 ml, 2.0 eq.). The solution was stirred for 1 hour at 0°C, then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave a white solid which was triturated with hexane to remove a yellow impurity and recrystallized from hot hexane/EtOAc, to give title product, 256 mg (51%).

TLC (1:1) Hexane:EtOAc R_f=0.46. Trace R_f=0.62.
UV + CeMO.

Product streaks to baseline.

Anal Calcd for C₂₃H₂₃NO₂: C, 79.97; H, 6.71;
N, 4.05
Found: C, 79.62; H, 6.56; N, 3.92

Example 175

N-(1,1-Dimethylethyl)-N-hydroxy[1,1'-biphenyl]-4-carboxamide

To a stirring solution of 1,1'-biphenyl-carboxylic acid (1.0 g, 5.1 mmol) in 10 ml of dry benzene under argon, was added oxalyl chloride (0.48 ml, 2.0 eq.). To this solution was added DMF dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (2 drops). The mixture was stirred for 1 hour and then reduced on the rotovap without heating. The crude product, a white solid, was dissolved in 5 ml of THF and added dropwise to a 0°C solution of N-t-butylhydroxylamine

hydrochloride (1.0 g, 1.6 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (2.0 ml, 3.0 eq.). The solution was stirred for 1 hour at 0°C, then allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave a white solid which was recrystallized from hot hexane/EtOAc, to give title product, 540 mg (40%), as long white needles.

TLC (1:1) Hexane:EtOAc R_f=0.42. Trace R_f=0.68. UV + CeMO. Product streaks to baseline.

Anal Calcd for C₁₇H₁₉NO₂: C, 75.81; H, 7.11;
N, 5.20
Found: C, 75.74; H, 7.21; N, 5.21

Example 176

N-Cyclohexyl-N-hydroxy[1,1'-biphenyl]-4-carboxamide

To a stirring solution of 1,1'-biphenyl carboxylic acid (500 mg, 2.5 mmol) in 10 ml of dry benzene under argon was added oxalyl chloride (0.24 ml, 1.1 eq.). To this solution was added DMF dropwise in 10 minute intervals until no gas was evolved and the solution turned slightly cloudy (two drops). The mixture was stirred for 1 hour then reduced on the rotovap without heating. The crude product, a white solid, was dissolved in THF (5 ml) and added dropwise to a 0°C solution of N-cyclohexylhydroxylamine hydrochloride (766 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine

(1.1 ml, 3.0 eq.) added sequentially. The solution was stirred for 0.5 hour at 0°C then allowed to warm to room temperature and stir for an additional 6 hours. The reaction mixture was
5 diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration
10 in vacuo gave a white solid which was recrystallized from hot hexane/EtOAc to give title product, 615 mg (82%) as long white needles.

TLC (1:1) Hexane:EtOAc R_f=0.46, trace R_f=0.54 UV + PMA. Product streaks to baseline.

15 Anal calcd for C₁₉H₂₁NO₂: C, 77.26; H, 7.17;
N, 4.74

Found: C, 77.24; H, 7.13; N, 4.65

Example 177

20 N-Hydroxy-N-methyl-4-pentylbenzamide

To a 0°C solution of N-methylhydroxylamine hydrochloride (793 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (198 ml, 3.0 eq.) was added 4-(n-pentyl) benzoic acid chloride (1.0 ml,
25 4.75 mmol). The solution was stirred for 0.5 hour at 0°C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with
30 H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave a yellow oil which was flash chromatographed in LPS-1 silica gel eluting with (1:1) hexane/EtOAc. Product containing fractions were c ncentrated

in vacuo to yield title product, 380 mg (37%) as a light yellow oil.

TLC (1:1) Hexane:EtOAc, $R_f=0.29$, UV + PMA.

5 Product streaks to baseline.

Anal Calcd for $C_{13}H_{19}NO_2$: C, 70.56; H, 8.65;
N, 6.33

Found: C, 70.73; H, 8.58; N, 6.08

10

Example 178

4-Heptyl-N-hydroxy-N-methylbenzamide

To a 0°C solution of N-methylhydroxylamine hydrochloride (701 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (1.75 ml, 3.0 eq.) was added 4-n-heptyl benzoic acid chloride (1.0 g, 4.2 mmol). The solution was stirred for ½ hour at 0°C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave an oil which was flash chromatographed on LPS-1 silica gel eluting with (1:1) hexane:EtOAc. Product containing fractions were concentrated in vacuo to yield title product, 448 mg (43%) as a light yellow oil which solidified upon standing.

25
30 TLC (1:1) Hexane:EtOAc $R_f=0.18$, UV + PMA. Product streaks to baseline.

Anal Calcd for $C_{15}H_{23}NO_2$: C, 72.25; H, 9.30;
N, 5.62

Found: C, 72.30; H, 9.36; N, 5.43

5

Example 179

4-(Cyclohexyloxy)-N-hydroxy-N-methylbenzamide

A. 4-(1-Cyclohexenyloxy)benzoic acid

To a stirred solution of p-hydroxybenzoic acid (1.38 gm, 10 mmol) in THF (30 ml) is added sodium hydride (0.48 g, 20 mmol), followed by cyclohexenyl bromide (1.63 gm, 10 mM). The mixture is heated to reflux for 12 hours. After cooling the reaction mixture is poured into ethyl acetate and extracted with 1N NaOH (3X). The combined aqueous extracts are combined, acidified to pH 2 with concentrated HCl, and extracted 3X with ethyl acetate. The combined organic extracts are dried over Na_2SO_4 and evaporated under reduced pressure to afford the product.

20

B. 4-(Cyclohexyloxy)benzoic acid

To a stirring solution of Part A acid (500 mg, 2.3 mmol) in 20 ml of $CH_3OH/EtOAc$ (1:1) was added rhodium/alumina (5%) 50 mg under argon. Hydrogen gas was added and the reaction was allowed to stir under H_2 (balloon) for $\frac{1}{2}$ hour. The mixture was filtered (Millipore) and concentrated in vacuo to yield a white solid which was carried directly on to the next step.

25

C. 4-(Cyclohexyloxy)-N-hydroxy-N-methyl-
benzamide

To a stirring solution of Part B acid (375 mg, 1.7 mmol) in 10 ml of dry benzene under argon, was added oxalyl chloride (0.16 ml, 1.1 eq.). To this solution was added DMF dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (2 drops). The mixture was stirred for 1 hour and then reduced on the rotovap without heating. The crude product, mixed with 5 ml of THF, was added dropwise to a 0°C solution of N-methylhydroxylamine hydrochloride (284 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (0.71 ml, 3.0 eq.). The solution was stirred for ½ hour at 0°C, then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer washed with H₂O, 1M HCl in vacuo gave a white solid which was recrystallized from hexane/EtOAc to give title product, 277 mg (88%).

TLC (1:1) Hexane:EtOAc R_f=0.19, UV + CeMO.
Product streaks to baseline.

Anal Calcd for C₁₄H₁₉NO₃: C, 67.45; H, 7.68;
N, 5.62

Found: C, 67.44; H, 7.71; N, 5.40

Example 180N-Hydroxy-N-methyl-4-(3-phenylpropoxy)benzamideA. 4-(3-Phenylpropoxy)benzoic acid,
methyl ester

5 To a solution of p-hydroxybenzoic
acid, methyl ester (2.0 g, 13.2 mmol) in
toluene/DMF (2:1) under argon was added NaH (630
mg, 2.0 eq.). After stirring for 15 minutes
3-phenylpropyl bromide (3.0 ml, 1.5 eq.) was added
10 and the mixture refluxed for 4 hours. The solution
was diluted with EtOAc and water. The organic
layer was washed with H₂O, 5% KHSO₄ and brine, then
dried over anhydrous MgSO₄. Concentration
15 in vacuo gave a yellow oil which solidified upon
standing. Recrystallization from hexane/EtOAc
gave title compound, a cream colored solid, 1.35 g
(38%).

B. 4-(3-Phenylpropoxy)benzoic acid

20 To a stirred solution of the Part A methyl
ester (1.35 g, 5.0 mmol) in CH₃OH (60 ml) and THF
(10 ml) was added a 2.0 N NaOH solution (7.5 ml,
3.0 eq.) and the mixture was refluxed under argon
overnight, then quenched with 0.25 M citric acid.
25 Concentration in vacuo, followed by dilution with
EtOAc and washes of H₂O, 1N HCl, and brine, gave a
white solid after concentration and drying over
anhydrous MgSO₄. Recrystallization from
hexane/EtOAc gave title acid, 1.04 g (81%).

C. N-Hydroxy-N-methyl-4-(3-phenylpropoxy)-benzamide

To a stirring solution of Part B acid (300 mg, 1.17 mmol) in 10 ml of dry benzene under argon was added oxalyl chloride (0.57 ml, 3.8 eq.). To this solution was added DMF dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (2 drops). The mixture was stirred for 24 hours, then reduced on the rotovap without heating. The crude product, a white solid, was diluted with 5 ml of THF and added dropwise to a 0°C solution of N-methylhydroxylamine hydrochloride (195 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (0.5 ml, 3.0 eq.). The solution was stirred for ½ hour at 0°C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave a white solid which was recrystallized from hot hexane/EtOAc, to give title product, 286 mg (91%).

TLC (1:1) Hexane:EtOAc R_f=0.17, UV + CeMO. Product streaks to baseline.

Anal Calcd for C₁₇H₁₇NO₃: C, 71.56; H, 6.71;
N, 4.91

Found: C, 71.84; H, 6.84; N, 4.82

Example 181

N-Hydroxy-4-(4-phenylbutyl)-N-(phenylmethyl)benzamide

5 A. 4-(4-Phenylbutyl)-N-(tetrahydropyran-2-yloxy)benzamide

To a 0°C solution of 4-(4-phenylbutyl)-benzoic acid (700 mg, 2.8 mmol) in 40 ml of CH₂Cl₂ under argon was added tetrahydropyranyl hydroxylamine (H₂N-OTHP) (654 mg, 2.0 eq.), 1-hydroxybenzotriazole (HOBT) (460 mg, 1.2 eq.), N,N'-dicyclohexylcarbodiimide (700 mg, 1.2 eq.) sequentially. After 0.5 hour at 0° the solution was allowed to warm to room temperature and stir under argon for 4 hours. The solution was filtered, concentrated
15 in vacuo to yield a white solid which was chromatographed on LPS-1 silica gel eluting with 6:4 hexane/EtOAc. Product containing fractions were evaporated to give title compound, an oil 1.0 g (~100%).

20 B. 4-(4-Phenylbutyl)-N-(phenylmethyl)-N-(tetrahydropyran-2-yloxy)benzamide

To a stirring solution of Part A compound (350 mg, 1.0 mmol) under argon in 10 ml of dry
25 toluene was added NaH (1.1 eq., 27 mg). The mixture was allowed to stir for 30 minutes and then benzyl bromide (0.37 ml, 3.0 eq.) was added. The mixture was heated to reflux and allowed to stir for 1.5 hours. The reaction was cooled and
30 diluted with EtOAc and partitioned over 5% KHSO₄. The organic phase was washed with brine, dried over anhydrous MgSO₄ and evaporated to yield yellow oil which was chromatographed on LPS-1 silica gel eluting with hexane:EtOAc. Product

containing fractions were evaporated to give title compound (240 mg, 59%) as a pale yellow oil.

5 C. N-Hydroxy-4-(4-phenylbutyl)-N-
(phenylmethyl)benzamide

To a stirring solution of Part B compound (240 mg, 0.6 mmol) in 10 ml of CH₃OH under argon was added pyridinium-p-toluenesulfonate (178 mg; 1.2 eq.). The solution was heated to 60°C in an oil bath for 24 hours. The solution was diluted with EtOAc and washed with 10 ml of brine, diluted with 10 ml of water. The organic layer was washed with brine (10 ml) and dried over MgSO₄ (anhydrous) and reduced in vacuo to yield an off-white solid which was recrystallized from hexane/EtOAc to give title product (130 mg, 62%) as a white solid with m.p. 83.5°-85.0°C.


20 TLC (2:1) hexane-EtOAc; R_f=0.29, UV + CeMO.
Product streaks to baseline.

Anal Calcd for C₂₄H₂₅NO₂: C, 80.19; H, 7.01;
N, 3.90

Found: C, 79.94; H, 7.08; N, 3.77

CLAIMS

1. A compound having the structure



wherein R¹ is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl, or

$(\text{CH}_2)_n\overset{\text{O}}{\parallel}\text{C}-\text{X}$ wherein n is 1 to 4 and X is hydroxy, alkoxy, amino, C₁-C₄-alkylamino or C₁-C₄-dialkylamino;

R² is hydrogen or lower alkyl; and

R³ is C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, aryl, aryl-alkyl, cycloalkyl, aryl-alkenyl, lower alkoxy, lower alkenyloxy, aryl-alkoxy, aryloxy or cycloalkyloxy, but when R³ is aryl, R¹ is other than H, including pharmaceutically acceptable monobasic and dibasic salts thereof.

2. The compound as defined in Claim 1

wherein R¹ is alkyl or $-(\text{CH}_2)_n\overset{\text{O}}{\parallel}\text{C}-\text{X}$.

3. The compound as defined in Claim 1 wherein R¹ is alkyl, R² is H and R³ is alkyl.

4. The compound as defined in Claim 1 wherein R³ is phenyl, phenylalkyl, phenylalkenyl, C₁ to C₂₀ alkyl or C₃ to C₂₀ alkenyl.

5. The compound as defined in Claim 1 having the name 4-decyl-N-hydroxy-N-methylbenzamide.

6. The compound as defined in Claim 1 having the name (Z)-4-[[4-(1-decenyl)benzoyl]-hydroxyamino]butanoic acid.

7. The compound as defined in Claim 1 having the name (Z)-4-[[4-(1-decenyl)benzoyl]-hydroxyamino]butanoic acid including all stereoisomers thereof.

8. The compound as defined in Claim 1 having the name 4-[(3-decylbenzoyl)hydroxyamino]-butanoic acid.

9. The compound as defined in Claim 1 having the name 4-[(2-decylbenzoyl)hydroxyamino]-butanoic acid or its dilithium salt.

10. The compound as defined in Claim 1 having the name 4-[(4-decylbenzoyl)hydroxyamino]-butanoic acid, ethyl ester.

11. The compound as defined in Claim 1 having the name (Z)-4-[[4-(1-decenyl)benzoyl]-methoxyamino]butanoic acid or its dicyclohexylamine salt(1:1) including all stereoisomers thereof.

12. The compound as defined in Claim 1 having the name N-(4-amino-4-oxobutyl)-4-decyl-N-hydroxybenzamide.

13. The compound as defined in Claim 1 having the name 4-[(4-decylbenzoyl)hydroxyamino]-butanoic acid.

14. The compound as defined in Claim 1 having the name 5-[(4-decylbenzoyl)hydroxyamino]-pentanoic acid.

15. The compound as defined in Claim 1 having the name (4-decyl-N-hydroxybenzamido)-acetic acid.

16. The compound as defined in Claim 1 having the name 4-[[3-(1-decenyl)benzoyl]hydroxy-amino]butanoic acid.

17. The compound as defined in Claim 1 having the name (Z)-4-(1-decenyl)-N-hydroxybenzamide, including all stereoisomers thereof.

18. The compound as defined in Claim 1 having the name N-hydroxy-N-methyl-4-(4-phenylbutyl)benzamide.

19. The compound as defined in Claim 1 having the name N-hydroxy-N-methyl[1,1'-biphenyl]-4-carboxamide.

20. The compound as defined in Claim 1 having the name N-hydroxy-N-methyl-4-(4-phenylbuten-1-yl)benzamide.

21. The compound as defined in Claim 1 having the name N-hydroxy-4-(4-phenylbutyl)-N-(phenylmethyl)benzamide.

22. The compound as defined in Claim 1 having the name N-hydroxy-N-phenyl-4-(4-phenylbutyl)benzamide.

23. The compound as defined in Claim 1 having the name N-(1,1-dimethylethyl)-N-hydroxy[1,1'-biphenyl]-4-carboxamide.

24. The compound as defined in Claim 1 having the name N-cyclohexyl-N-hydroxy[1,1'-biphenyl]-4-carboxamide.

25. The compound as defined in Claim 1 having the name N-hydroxy-N-methyl-4-pentylbenzamide.


26. The compound as defined in Claim 1 having the name 4-heptyl-N-hydroxy-N-methylbenzamide.

27. The compound as defined in Claim 1 having the name 4-(cyclohexyloxy)-N-hydroxy-N-methylbenzamide.

28. The compound as defined in Claim 1 having the name N-hydroxy-N-methyl-4-(3-phenylpropoxy)benzamide.

29. The compound as defined in Claim 1 having the name N-(1,1-dimethylethyl)-N-hydroxy-4-(4-phenylbutyl)benzamide.

30. A process for preparing compounds having the formula



wherein R^1 is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl, or

$(CH_2)_n \overset{\overset{O}{\parallel}}{C}-X$ wherein n is 1 to 4 and X is hydroxy, alkoxy, amino, C_1-C_4 -alkylamino or C_1-C_4 -dialkylamino;


R^2 is hydrogen or lower alkyl; and

R^3 is C_1-C_{20} alkyl, C_3-C_{20} alkenyl, aryl, aryl-alkyl, cycloalkyl, aryl-alkenyl, lower alkoxy, lower alkenyloxy, aryl-alkoxy, aryloxy or cycloalkyloxy, but when R^3 is aryl, R^1 is other than H, including pharmaceutically acceptable monobasic and dibasic salts thereof which comprises


A) when R^1 is lower alkyl, aryl, cycloalkyl,

aralkyl or $(CH_2)_n \overset{\overset{O}{\parallel}}{C}$ -lower alkoxy, R^2 is hydrogen and R^3 is C_1-C_{20} alkyl, arylalkyl, cycloalkyloxy, lower alkoxy or aryloxy reacting a compound having the formula

II




wherein R^{3a} is C_3 - C_{20} alkenyl, alkenyloxy, aryloxy, cycloalkyloxy or arylalkenyl with a compound having the formula




wherein Hal is I, Br, or Cl and R^{1a} is the same as R^1 wherein R^1 is lower alkyl, aryl, cycloalkyl,

aralkyl or $(\text{CH}_2)_n-\text{C}(=\text{O})$ -lower alkoxy to yield a compound having the formula




and reacting compound III with hydrogen in the presence of palladium hydroxide on a carbon catalyst to form compounds of formula




wherein R^1 , R^2 and R^3 are as defined in this subsection A and when

B) R^1 is $(CH_2)_n-C(=O)OH$ in formula I, reacting a compound of formula IV when R^1 is $(CH_2)_nCO_2alkyl$ with an alkali metal hydroxide in an organic solvent and when

C) R^1 is $-CH_2-C(=O)X$ when X is OH or alkoxy reacting a compound of the formula




with hydrogen in the presence of palladium hydroxide on a carbon catalyst to form the compound of the formula




and hydrolyzing the compound of formula IVa to the corresponding acid and when

D) R^3 is C_3-C_{20} alkenyl, arylalkenyl or lower alkenyl removing the tetrahydropyranyl or methoxymethyl protecting group from the compounds of formula III or IIIb with acetic acid or when the protecting group is methylthiomethyl, treating the compounds of formula III or IIIb with $CuO-CuCl_2$ in aqueous acetone and

E) when R^1 is $-(CH_2)_n-\overset{\overset{O}{||}}{C}-X$ and X is amino, alkylamino or dialkylamino reacting a compound of the formula




with ammonium hydroxide when X is amino or with an alkylamine or dialkylamine when X is alkylamino or dialkylamino in the presence of an activating agent, organic base and organic solvent and removing a benzyl protecting group to form the compound




wherein R^3 is alkyl and X is amino or alkylamino and removing a tetrahydropyranal protecting group wherein R^3 is alkenyl.

31. A process according to Claim 30 wherein R^1 is hydrogen prepared by removing the protecting group of compound II in the presence of an acid catalyst to form the compound




wherein R^2 is hydrogen and R^3 is C_3-C_{20} .

32. A process according to Claim 30 wherein R^2 is alkyl and R^3 is C_1-C_{20} alkyl or aryl-alkyl prepared by reacting a compound having the formula




with halide C to form a compound of the formula



wherein R^{3a} is C_3 - C_{20} alkenyl or aryl-alkenyl and where compound VI is reduced to form the corresponding compound wherein R_3 is C_3 - C_{20} alkyl.

33. A process for preparing compounds of formula I




wherein R^1 is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl, or

$(CH_2)_n \overset{\overset{O}{\parallel}}{C}-X$ wherein n is 1 to 4 and X is hydroxy, alkoxy, amino, C_1 - C_4 -alkylamino or C_1 - C_4 -dialkylamino;


R^2 is hydrogen or lower alkyl; and

R^3 is C_1 - C_{20} alkyl, C_3 - C_{20} alkenyl, aryl, aryl-alkyl, cycloalkyl, aryl-alkenyl, lower alkoxy, lower alkenyloxy, aryl-alkoxy, aryloxy or cycloalkyloxy, but when R^3 is aryl, R^1 is other than H, including pharmaceutically acceptable monobasic and dibasic salts thereof which comprises


A) wherein R^2 is hydrogen reacting a compound of the formula



with a compound of the formula




to yield the compounds of the formula




and B) when R^2 is alkyl reacting compounds of formula VII with a base and an alkyl halide.


34. A process for preparing compounds of formula I which comprises reacting a compound of the formula




with an amine salt of the formula



to form a compound of the formula



esterifying compound X and then deprotecting followed by hydrolysis to yield



35. A process according to Claims 30, 31 and 32 wherein the protecting group is benzyl, tetrahydropyranyl, methylthiomethyl or methoxymethyl.

36. A process according to Claim 33 wherein R^3 is aryl or cycloalkyl.

37. A process according to Claims 30, 31 and 32 wherein the reaction temperature is from 50° to 110°C .